CA2128078C - Nutritional product for trauma and surgery patients - Google Patents
Nutritional product for trauma and surgery patients Download PDFInfo
- Publication number
- CA2128078C CA2128078C CA002128078A CA2128078A CA2128078C CA 2128078 C CA2128078 C CA 2128078C CA 002128078 A CA002128078 A CA 002128078A CA 2128078 A CA2128078 A CA 2128078A CA 2128078 C CA2128078 C CA 2128078C
- Authority
- CA
- Canada
- Prior art keywords
- nutritional product
- liquid nutritional
- product according
- vitamin
- calories
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 91
- 208000014674 injury Diseases 0.000 title abstract description 48
- 230000008733 trauma Effects 0.000 title abstract description 34
- 238000001356 surgical procedure Methods 0.000 title abstract description 15
- 235000018102 proteins Nutrition 0.000 claims abstract description 56
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000007788 liquid Substances 0.000 claims abstract description 35
- 150000002632 lipids Chemical class 0.000 claims abstract description 30
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 23
- 229930064664 L-arginine Natural products 0.000 claims abstract description 22
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 19
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 17
- 229960004232 linoleic acid Drugs 0.000 claims abstract description 17
- 230000000153 supplemental effect Effects 0.000 claims abstract description 12
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 10
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims description 118
- 229940024606 amino acid Drugs 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 239000004475 Arginine Substances 0.000 claims description 19
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 19
- 235000009697 arginine Nutrition 0.000 claims description 17
- 150000001720 carbohydrates Chemical class 0.000 claims description 16
- 235000014633 carbohydrates Nutrition 0.000 claims description 16
- 102000004407 Lactalbumin Human genes 0.000 claims description 15
- 108090000942 Lactalbumin Proteins 0.000 claims description 15
- 239000000828 canola oil Substances 0.000 claims description 12
- 235000019519 canola oil Nutrition 0.000 claims description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 11
- 239000002285 corn oil Substances 0.000 claims description 11
- 235000005687 corn oil Nutrition 0.000 claims description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 9
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 9
- 235000013734 beta-carotene Nutrition 0.000 claims description 9
- 239000011648 beta-carotene Substances 0.000 claims description 9
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 9
- 229960002747 betacarotene Drugs 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 235000019155 vitamin A Nutrition 0.000 claims description 9
- 239000011719 vitamin A Substances 0.000 claims description 9
- 229940045997 vitamin a Drugs 0.000 claims description 9
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 9
- 102000011632 Caseins Human genes 0.000 claims description 8
- 108010076119 Caseins Proteins 0.000 claims description 8
- 235000013325 dietary fiber Nutrition 0.000 claims description 8
- 229940080237 sodium caseinate Drugs 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 229920002261 Corn starch Polymers 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 239000008120 corn starch Substances 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 235000001465 calcium Nutrition 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- 229930003448 Vitamin K Natural products 0.000 claims 2
- 229960005069 calcium Drugs 0.000 claims 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 235000001055 magnesium Nutrition 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 229940055726 pantothenic acid Drugs 0.000 claims 2
- 235000019161 pantothenic acid Nutrition 0.000 claims 2
- 239000011713 pantothenic acid Substances 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 235000014786 phosphorus Nutrition 0.000 claims 2
- 235000019157 thiamine Nutrition 0.000 claims 2
- 239000011721 thiamine Substances 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 235000019168 vitamin K Nutrition 0.000 claims 2
- 239000011712 vitamin K Substances 0.000 claims 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 229940046010 vitamin k Drugs 0.000 claims 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000002002 slurry Substances 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000013019 agitation Methods 0.000 description 17
- 229960003121 arginine Drugs 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 230000006378 damage Effects 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 230000015556 catabolic process Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 208000028399 Critical Illness Diseases 0.000 description 7
- 208000002720 Malnutrition Diseases 0.000 description 7
- 206010040047 Sepsis Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 229960003080 taurine Drugs 0.000 description 7
- 229960004203 carnitine Drugs 0.000 description 6
- 239000000413 hydrolysate Substances 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 235000000824 malnutrition Nutrition 0.000 description 6
- 230000001071 malnutrition Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 235000019742 Vitamins premix Nutrition 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 230000002992 thymic effect Effects 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010020674 Hypermetabolism Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000004251 balanced diet Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 208000037974 severe injury Diseases 0.000 description 3
- 230000009528 severe injury Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- -1 Potassium Iodide Potassium Citrate Magnesium Chloride Potassium Chloride Potassium Phosphate Chemical compound 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000008425 Protein deficiency Diseases 0.000 description 2
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000020538 atrophic muscular disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004678 mucosal integrity Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 230000004844 protein turnover Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- AOKLUWFWNZLQSN-LROMGURASA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-6-aminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-n-[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]butanediamide Chemical group NCCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(N)=O)CC1=CC=C(O)C=C1 AOKLUWFWNZLQSN-LROMGURASA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BHCBLTRDEYPMFZ-UHFFFAOYSA-N 5-acetamido-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound CC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I BHCBLTRDEYPMFZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 241000370685 Arge Species 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010058892 Carnitine deficiency Diseases 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 108010006701 N-acetyllysyl-arginyl-tyrosyl-asparaginyl-leucinamide Proteins 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003166 hypermetabolic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 201000009868 osmotic diarrhea Diseases 0.000 description 1
- 208000028719 osmotic diarrheal disease Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 1
- MYVIATVLJGTBFV-UHFFFAOYSA-M thiamine(1+) chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N MYVIATVLJGTBFV-UHFFFAOYSA-M 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/80—Geriatric
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/801—Pediatric
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/81—Energy rations, e.g. emergency rations, survival rations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A liquid nutritional product for trauma and surgery patients has a caloric density of about 1.2 to 1.5 Kcal/mL and a calo-rie to nitrogen ratio of about 112:1 to 145:1. A portion of the protein system comprises partially digested protein, and supplemen-tal L-arginine provides about 1-3 % of the total calories in the product. The lipid system has a ratio of linoleic acid to alpha lino-leic acid in the range of about 3.5:1 to about 5.5:1.
Description
~~a ~ n ~ ;f'A ~ ,~1 .~ ~ ~ ~ ~~ ~~J
WO 93/1659~~ PCT/US93/01100 NUTRITIONAL PRODUCT FOR TRAUMA AND SURGERY PATIENTS
FIELD OF THE INVENTION
The present invention relates to a nutritional product for persons subjected to trauma or surgery.
BACKGROUND OF THE INYENTION
Trauma is a leading health problem in the United States today. Trauma is the number' one killer of young adults and it ranks third overall, following heart disease and cancer. For every American who dies as a result of trauma, there are three Americans permanently disabled (500,000 permanent disabilities/year).
Approximately 50f. of deaths from trauma occur within seconds of the injury.
Trauma prevention is the only way to alter deaths which occur immediately following injury. A second peak in deaths occurs within two or three hours after the trauma and is dependent upon available intervention and treatment of the life-threatening aspects of the injury. The third peak occurs days or even weeks following the injury and is usually caused by sepsis and/or multiple organ failure. Sepsis may be defined as the presence of bacterial infection.
Septicemia continues to be a problem in the critically ill, surgical or traumatized patient. Death secondary to systemic sepsis is not uncommon and may occur two to four weeks after the initial injury.
Severe injury or trauma, including surgery, is associated with loss of the body's nutrient stores due both to the injury itself and the resulting catabolic state. For optimal recovery, critically ill patients need proper nutritional intake. Lack of it can result in malnutrition-associated complications, including prolonged negative nitrogen balance, depletion of somatic and visceral protein levels, immune incompetence, increased risk of infection, and other complications associated with morbidity and mortality. A primary objective of nutritional support for the traumatized person is to replace or maintain the body's normal level of nutrients by providing adequate energy substrates, protein, and other nutrients essential for tissue repair and recovery.
While nutrients may be provided by either parenteral or enteral routes, clinicians are making greater efforts to use the enteral route in light of research showing that enterai feeding confers certain physiologic benefits not seen with parenteral feeding. Published studies have reported that early enteral feeding provides energy and nutrients essential for optimal healing and immunocompe tence, helps maintain the gut mucosal integrity, and may blunt catabolic effects and normalize blood glucose levels. Certain nutrients have effects on the gastrointestinal tract and immune system that go beyond the provision of nutrition. For example, beta-carotene, lactalbumin, and arginine are known i~o have specific physiologic benefits that are especially important for trauma and surgical patients.
~.~.?c~t~'~~
WO 93/1659~~ PCT/US93/01100 NUTRITIONAL PRODUCT FOR TRAUMA AND SURGERY PATIENTS
FIELD OF THE INVENTION
The present invention relates to a nutritional product for persons subjected to trauma or surgery.
BACKGROUND OF THE INYENTION
Trauma is a leading health problem in the United States today. Trauma is the number' one killer of young adults and it ranks third overall, following heart disease and cancer. For every American who dies as a result of trauma, there are three Americans permanently disabled (500,000 permanent disabilities/year).
Approximately 50f. of deaths from trauma occur within seconds of the injury.
Trauma prevention is the only way to alter deaths which occur immediately following injury. A second peak in deaths occurs within two or three hours after the trauma and is dependent upon available intervention and treatment of the life-threatening aspects of the injury. The third peak occurs days or even weeks following the injury and is usually caused by sepsis and/or multiple organ failure. Sepsis may be defined as the presence of bacterial infection.
Septicemia continues to be a problem in the critically ill, surgical or traumatized patient. Death secondary to systemic sepsis is not uncommon and may occur two to four weeks after the initial injury.
Severe injury or trauma, including surgery, is associated with loss of the body's nutrient stores due both to the injury itself and the resulting catabolic state. For optimal recovery, critically ill patients need proper nutritional intake. Lack of it can result in malnutrition-associated complications, including prolonged negative nitrogen balance, depletion of somatic and visceral protein levels, immune incompetence, increased risk of infection, and other complications associated with morbidity and mortality. A primary objective of nutritional support for the traumatized person is to replace or maintain the body's normal level of nutrients by providing adequate energy substrates, protein, and other nutrients essential for tissue repair and recovery.
While nutrients may be provided by either parenteral or enteral routes, clinicians are making greater efforts to use the enteral route in light of research showing that enterai feeding confers certain physiologic benefits not seen with parenteral feeding. Published studies have reported that early enteral feeding provides energy and nutrients essential for optimal healing and immunocompe tence, helps maintain the gut mucosal integrity, and may blunt catabolic effects and normalize blood glucose levels. Certain nutrients have effects on the gastrointestinal tract and immune system that go beyond the provision of nutrition. For example, beta-carotene, lactalbumin, and arginine are known i~o have specific physiologic benefits that are especially important for trauma and surgical patients.
~.~.?c~t~'~~
Severe injury and major surgery causes abrupt changes in body metabolism.
These changes vary with the type of trauma, previous health status, and medical care. Hormonally mediated hypermetabolism, catabolism, elevated basal metabolic rate and nitrogen excretion, altered fluid and electrolyte balance, synthesis of acute phase proteins, inflammation, and immunosuppression are often observed after severe injury, major surgery, or critical illness. The gastrointestinal tract is frequently affected by trauma or surgery. Blood flow may be reduced by hemorrhage, and the resulting loss of oxygen and nutrients may damage mucosal cells. However, the presence of intraluminal nutrients helps protect the gastrointestinal tract.
Epithelial cells such as those lining the gut are an important barrier against bacaerial infection. The importance of the "first line of defense"
provided by epithelial cells is evident, for example, in the patient suffering from a serious burn who is at risk of infection due to the destruction of skin.
Appropriate enteral nutrition following injury may minimize malnutrition, provide nutrients to the immune system and maintain the gut epithel ial which acts as a barrier to translocation of bacteria . This may help prevent the development of sepsis. Malnutrition may compromise the immune system and contribute to the high incidence of septic complications. It has been reported that cell-mediated immunity is reduced in proportion to the level of malnutrition of the critically ill patient.
Following severe trauma and major surgery, gastrointestinal disturbances such as diarrhea, abdominal bloating and aspiration, have been associated with enteral feeding. These disturbances are caused by complex interactions between the trauma response, antibiotic and drug therapy as well as the enteral feeding.
If at all possible, enteral feeding is advised to maintain mucosal integrity.
The well-known "paralytic ileus" is usually confined to the stomach. The small intestine m;ay retain motility and often enteral nutritional through the small intestine c:an be used successfully. It is essential that the proper administration of nutrients, including water, be monitored in order to prevent a further deterioration of the nutrient status of the critically ill patient.
For those patients who are volume intolerant it is difficult to meet their caloric requirements with standard enteral nutritional products.
Both anabolic and catabolic processes are accelerated following severe trauma, although catabolism predominates. This response allows muscle breakdown to occur in order to provide amino acids for synthesis of proteins involved in immunologica~l response and tissue repair. However, some mobilization of protein and calcium can be attributed to bed rest. Disuse atrophy contributes to the muscle wasting and negative nitrogen balance frequently observed in the trauma patient.
The catabolism of trauma occurs as a mechanism to provide substrate through the breakdown of muscle tissue. Hypermetabolism also occurs; however, it is difficult to meet the caloric needs of the patient. Dietary protein may be utilized as an energy substrate which necessitates the excretion of nitrogenous products. Catabolism following trauma or major surgery may be obligatory and i t i s uncertai n whether i t coul d be al tered by the i ntake of 1 arge doses of protein. Overall negative nitrogen balance observed in traumatized and septic patients may be attributed to an inadequate caloric intake, rather than an insufficient protein intake.
The nutritional support of trauma and surgery patients has been extensively investigated in the prior art.
There are commercially available nutritional products intended for trauma or surgery patients. IMPACT" is a ready-to-use enteral formula which is distributed: by SANDOZ NUTRITION, Minneapolis, Minnesota, U.S.A.. IMPACf~
contains a much greater level of L-arginine than the product of the present invention, and has a lower caloric density than the product of the present invention. IMMUN-AIDS, a nutritional product for immunocompromised patients, is distributed by McGaw, Inc. of Irvine, California, U.S.A.. IMMUN-AID" is distributed in powdered form and contains intact protein and amino acids.
OSMOLITEe HN distributed by Ross Laboratories of Columbus, Ohio, U.S.A. is not specifically formulated for trauma or surgery patients but has often been employed for this purpose.
U.S. Patent 4,042,688 relates to a nutritional supplement, taken for example in tablet form, which contains predigested protein in the form of a gelatin hydrolysate. The gelatin hydrolysate used in that invention is made by hydrolyzing animal collagen, preferably a collagen derived from the skin of pork bellies, by means of enzymatic hydrolysis, and then spray drying the gelating solution. The predigested protein employed in the present invention is a higher quality protein than that derived from gelatin, and the nutritional product of the present invention provides a balanced diet rather than being a diet supplement.
U.S. Patent 4,438,144 teaches a nutritional composition that may be provided either enterally or parenterally, preferably parenterally, wherein the amino acids comprise from about 70 to 100% valine, isoleucine and leucine, collectively. However, the nutritional product of the present invention is formulated t o provide a balanced diet and does not contain such high WO 93/1659:5 PCT/US93/01100 2 ~. ~ ('S ~.~ ri concentrations of these specific amino acids.
U.S. Patent 4,920,098 relates to a method of providing nutritional support as cardiac: therapy. This therapy regimen may be administered either parenterally or enterally. The nutritional product is formulated to provide energy and protein substrates that are especially beneficial to cardiac tissues. Although the caloric distribution taught in this patent is similar to that of the nutritional product disclosed herein, the new product contains a much different protein system and is formulated for a different patient population.
U.S. Patent 5,053,387 teaches a nutritional composition containing intact protein, preferably whey, and contains arginine in the amount of about l-3X of the total energy intake. In a preferred embodiment the lipid consists of a mixture of equal amounts of fish oil and safflower oil. The caloric distribution of the composition taught in this patent is substantially different from that of the nutritional product of the present invention.
Published Australian Patent Application 36917/84 relates to an amino acid solution that may be provided either enterally or parenterally to a patient, but does not i:each a composition for providing a balanced diet as in the present invention.
Published European Patent Application No. 0 367 724 teaches a nutritional composition containing intact protein, arginine and marine oil. It has a caloric density which is substantially lower than that of the nutritional product of the present invention.
Published PCT application WO 91/09524 relates to a method of treating a patient having an impaired immune response due to trauma or surgery. The method involves providing the patient with about 15 to 35 grams of arginine per day.
Nutritional formulations for providing the arginine are disclosed in this PCT
application. Arginine is provided at a level of about 6.9 to 11.1 grams per 1,500 kcal by the nutritional product of the present invention (with 1,5000 kcal per day being the nutrient base of the new product).
European Patent Application 0 312 612 teaches a "nutritive emulsion"
containing an "amino acid preparation", a lipid and water. The caloric density of the "nutritive emulsion" is adjusted to a desired level by the amount of sugar in the emullsion.
Japans~se Patent Application Sho 61-192245 teaches that cows milk protein should he supplemant.ecJ by arc~ininr. at a level of 3.5 - 7.0~: of the amino acids in the product for a nutritional product for infants. The nutritional product of the present invention has an amino acid profile containing 9.0 to 13.8%
arginine.
4a SUi~IARY OF THE INVENTION
In accordance with the invention there is provided a liquid nutritional. product comprising: a protein system comprising by weight about 20-30-°s lactalbumin hydro-lysate, about 60-70°s partially hydrolyzed, sodium case-inate, and about 8-14% L-arginine, supplemental L-arginine providing about 1-3% of the total calories in the nutritional product; and a lipid system hazing a ratio of linoleic acid to alpha linoleic acid i.n the range of about 3.5:1 to about 5.5:1, said nutritional product having a ca=Loric density it the range of about 1.2 to 1.5 kcal/ml and a calorie to nitrogen ratio of about 112:1 to about: 145:1.
In accordance with another aspect of the invention there is provided a liquid nutritional product comprising: (a) a protein system which provides about 18-24% of the calories provided by the product, said protein system including (i) partially hydrolyzed protein and (ii) supplemental L-arginine in an amount sufficient to provide about 1-3% of the total calories provided by the product; (b) a lipid system which provides about 20-30%
of the calories provided by the product, said lipid system having a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1; and (c) carbohydrates which :provide about 46-62% of the calories provided by the product, the product having a caloric density in the range of about 1.2 to 1.5 kcal/ml a calorie to nitrogen ratio of about 112:1 to about 145:1, and having the following amino acid profile:
4b AMINO ACID g/100g protein Histidine 1.7 2.4 -Isoleucine 4.1 5.1 -Leucine 7.9 12.5 -Lysine 5.5 9.4 -Methionine 2.1 2.9 -Phenylalanine 3.5 4.9 -Threonine 3.9 5.3 -Tryptophan 1.1 2.0 -Valine 4.8 6.5 -Alanine 2.9 4.4 -Arginine (Includes inherent arginine)9.0 14.5 -Aspartic Acid 6.5 10.00 -Cystine 0.7 2.2 -Glutamic Acid 17.5 - 20.5 Glycine 1.5 1.9 -Proline 6.5 9.0 -Serine 4.8 5.1 -Tyrosine 3.7 5.3.
-2 1 280 ?8 4c In accordance with yet another aspect of the invention there is provided a liquid nutritional product compri:>ing (a) a protein system comprising by weight about 20-30$ lactalbumin hydrolysate, about 62-68$ partially hydrolyzed sodium caseinate, and about 8-12$ L-arginine, supplemental L-arginine providing about 1-3$ of the total caloriea in the nutritional product; (b) a lipid system comprising by weight about 35-45$ cano7_a oil, about 35-45$
medium chain triglycerides, and about 10-30~ corn oil, the lipid ~>ystem providing a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1 and (c) a carbohydrate system comprising hydrolyzed corn starch, the nutritional product having (i) a caloric density of about 1.3 kcal/ml, (ii) a caloric distribution such that about 18-24$ of the calories are provided by proteins, about 20-30$ of the ca7_ories are provided by lipids and about 46-62$ of the calories are provided by carbohydrates, (iii) the nutritional product: has a viscosity of not greater than 55 cps, and (iv) a calorie to nitrogen ratio of about 112:1 to about 145:1.
W
~.,.~a~ iJ~~
These changes vary with the type of trauma, previous health status, and medical care. Hormonally mediated hypermetabolism, catabolism, elevated basal metabolic rate and nitrogen excretion, altered fluid and electrolyte balance, synthesis of acute phase proteins, inflammation, and immunosuppression are often observed after severe injury, major surgery, or critical illness. The gastrointestinal tract is frequently affected by trauma or surgery. Blood flow may be reduced by hemorrhage, and the resulting loss of oxygen and nutrients may damage mucosal cells. However, the presence of intraluminal nutrients helps protect the gastrointestinal tract.
Epithelial cells such as those lining the gut are an important barrier against bacaerial infection. The importance of the "first line of defense"
provided by epithelial cells is evident, for example, in the patient suffering from a serious burn who is at risk of infection due to the destruction of skin.
Appropriate enteral nutrition following injury may minimize malnutrition, provide nutrients to the immune system and maintain the gut epithel ial which acts as a barrier to translocation of bacteria . This may help prevent the development of sepsis. Malnutrition may compromise the immune system and contribute to the high incidence of septic complications. It has been reported that cell-mediated immunity is reduced in proportion to the level of malnutrition of the critically ill patient.
Following severe trauma and major surgery, gastrointestinal disturbances such as diarrhea, abdominal bloating and aspiration, have been associated with enteral feeding. These disturbances are caused by complex interactions between the trauma response, antibiotic and drug therapy as well as the enteral feeding.
If at all possible, enteral feeding is advised to maintain mucosal integrity.
The well-known "paralytic ileus" is usually confined to the stomach. The small intestine m;ay retain motility and often enteral nutritional through the small intestine c:an be used successfully. It is essential that the proper administration of nutrients, including water, be monitored in order to prevent a further deterioration of the nutrient status of the critically ill patient.
For those patients who are volume intolerant it is difficult to meet their caloric requirements with standard enteral nutritional products.
Both anabolic and catabolic processes are accelerated following severe trauma, although catabolism predominates. This response allows muscle breakdown to occur in order to provide amino acids for synthesis of proteins involved in immunologica~l response and tissue repair. However, some mobilization of protein and calcium can be attributed to bed rest. Disuse atrophy contributes to the muscle wasting and negative nitrogen balance frequently observed in the trauma patient.
The catabolism of trauma occurs as a mechanism to provide substrate through the breakdown of muscle tissue. Hypermetabolism also occurs; however, it is difficult to meet the caloric needs of the patient. Dietary protein may be utilized as an energy substrate which necessitates the excretion of nitrogenous products. Catabolism following trauma or major surgery may be obligatory and i t i s uncertai n whether i t coul d be al tered by the i ntake of 1 arge doses of protein. Overall negative nitrogen balance observed in traumatized and septic patients may be attributed to an inadequate caloric intake, rather than an insufficient protein intake.
The nutritional support of trauma and surgery patients has been extensively investigated in the prior art.
There are commercially available nutritional products intended for trauma or surgery patients. IMPACT" is a ready-to-use enteral formula which is distributed: by SANDOZ NUTRITION, Minneapolis, Minnesota, U.S.A.. IMPACf~
contains a much greater level of L-arginine than the product of the present invention, and has a lower caloric density than the product of the present invention. IMMUN-AIDS, a nutritional product for immunocompromised patients, is distributed by McGaw, Inc. of Irvine, California, U.S.A.. IMMUN-AID" is distributed in powdered form and contains intact protein and amino acids.
OSMOLITEe HN distributed by Ross Laboratories of Columbus, Ohio, U.S.A. is not specifically formulated for trauma or surgery patients but has often been employed for this purpose.
U.S. Patent 4,042,688 relates to a nutritional supplement, taken for example in tablet form, which contains predigested protein in the form of a gelatin hydrolysate. The gelatin hydrolysate used in that invention is made by hydrolyzing animal collagen, preferably a collagen derived from the skin of pork bellies, by means of enzymatic hydrolysis, and then spray drying the gelating solution. The predigested protein employed in the present invention is a higher quality protein than that derived from gelatin, and the nutritional product of the present invention provides a balanced diet rather than being a diet supplement.
U.S. Patent 4,438,144 teaches a nutritional composition that may be provided either enterally or parenterally, preferably parenterally, wherein the amino acids comprise from about 70 to 100% valine, isoleucine and leucine, collectively. However, the nutritional product of the present invention is formulated t o provide a balanced diet and does not contain such high WO 93/1659:5 PCT/US93/01100 2 ~. ~ ('S ~.~ ri concentrations of these specific amino acids.
U.S. Patent 4,920,098 relates to a method of providing nutritional support as cardiac: therapy. This therapy regimen may be administered either parenterally or enterally. The nutritional product is formulated to provide energy and protein substrates that are especially beneficial to cardiac tissues. Although the caloric distribution taught in this patent is similar to that of the nutritional product disclosed herein, the new product contains a much different protein system and is formulated for a different patient population.
U.S. Patent 5,053,387 teaches a nutritional composition containing intact protein, preferably whey, and contains arginine in the amount of about l-3X of the total energy intake. In a preferred embodiment the lipid consists of a mixture of equal amounts of fish oil and safflower oil. The caloric distribution of the composition taught in this patent is substantially different from that of the nutritional product of the present invention.
Published Australian Patent Application 36917/84 relates to an amino acid solution that may be provided either enterally or parenterally to a patient, but does not i:each a composition for providing a balanced diet as in the present invention.
Published European Patent Application No. 0 367 724 teaches a nutritional composition containing intact protein, arginine and marine oil. It has a caloric density which is substantially lower than that of the nutritional product of the present invention.
Published PCT application WO 91/09524 relates to a method of treating a patient having an impaired immune response due to trauma or surgery. The method involves providing the patient with about 15 to 35 grams of arginine per day.
Nutritional formulations for providing the arginine are disclosed in this PCT
application. Arginine is provided at a level of about 6.9 to 11.1 grams per 1,500 kcal by the nutritional product of the present invention (with 1,5000 kcal per day being the nutrient base of the new product).
European Patent Application 0 312 612 teaches a "nutritive emulsion"
containing an "amino acid preparation", a lipid and water. The caloric density of the "nutritive emulsion" is adjusted to a desired level by the amount of sugar in the emullsion.
Japans~se Patent Application Sho 61-192245 teaches that cows milk protein should he supplemant.ecJ by arc~ininr. at a level of 3.5 - 7.0~: of the amino acids in the product for a nutritional product for infants. The nutritional product of the present invention has an amino acid profile containing 9.0 to 13.8%
arginine.
4a SUi~IARY OF THE INVENTION
In accordance with the invention there is provided a liquid nutritional. product comprising: a protein system comprising by weight about 20-30-°s lactalbumin hydro-lysate, about 60-70°s partially hydrolyzed, sodium case-inate, and about 8-14% L-arginine, supplemental L-arginine providing about 1-3% of the total calories in the nutritional product; and a lipid system hazing a ratio of linoleic acid to alpha linoleic acid i.n the range of about 3.5:1 to about 5.5:1, said nutritional product having a ca=Loric density it the range of about 1.2 to 1.5 kcal/ml and a calorie to nitrogen ratio of about 112:1 to about: 145:1.
In accordance with another aspect of the invention there is provided a liquid nutritional product comprising: (a) a protein system which provides about 18-24% of the calories provided by the product, said protein system including (i) partially hydrolyzed protein and (ii) supplemental L-arginine in an amount sufficient to provide about 1-3% of the total calories provided by the product; (b) a lipid system which provides about 20-30%
of the calories provided by the product, said lipid system having a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1; and (c) carbohydrates which :provide about 46-62% of the calories provided by the product, the product having a caloric density in the range of about 1.2 to 1.5 kcal/ml a calorie to nitrogen ratio of about 112:1 to about 145:1, and having the following amino acid profile:
4b AMINO ACID g/100g protein Histidine 1.7 2.4 -Isoleucine 4.1 5.1 -Leucine 7.9 12.5 -Lysine 5.5 9.4 -Methionine 2.1 2.9 -Phenylalanine 3.5 4.9 -Threonine 3.9 5.3 -Tryptophan 1.1 2.0 -Valine 4.8 6.5 -Alanine 2.9 4.4 -Arginine (Includes inherent arginine)9.0 14.5 -Aspartic Acid 6.5 10.00 -Cystine 0.7 2.2 -Glutamic Acid 17.5 - 20.5 Glycine 1.5 1.9 -Proline 6.5 9.0 -Serine 4.8 5.1 -Tyrosine 3.7 5.3.
-2 1 280 ?8 4c In accordance with yet another aspect of the invention there is provided a liquid nutritional product compri:>ing (a) a protein system comprising by weight about 20-30$ lactalbumin hydrolysate, about 62-68$ partially hydrolyzed sodium caseinate, and about 8-12$ L-arginine, supplemental L-arginine providing about 1-3$ of the total caloriea in the nutritional product; (b) a lipid system comprising by weight about 35-45$ cano7_a oil, about 35-45$
medium chain triglycerides, and about 10-30~ corn oil, the lipid ~>ystem providing a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1 and (c) a carbohydrate system comprising hydrolyzed corn starch, the nutritional product having (i) a caloric density of about 1.3 kcal/ml, (ii) a caloric distribution such that about 18-24$ of the calories are provided by proteins, about 20-30$ of the ca7_ories are provided by lipids and about 46-62$ of the calories are provided by carbohydrates, (iii) the nutritional product: has a viscosity of not greater than 55 cps, and (iv) a calorie to nitrogen ratio of about 112:1 to about 145:1.
W
~.,.~a~ iJ~~
DETAILED DESCRIPTION OF THE INVENTION
Table 1 presents the bill of materials for manufacturing 60,000 pounds of a liquid nutritional product according to the present invention.
INGREDIENT QUANTITY PER
60,000 LBS.
OF PRODUCT
WATER 42481.22 lbs HYDROLYZED t:ORNSTARCH 10517.95 lbs PARTIALLY HYDROLYZED SODIUM 2642.06 lbs LACTALBUMIN HYDROLYSATE 1093.71 lbs CANOLA OIL 837.60 lbs MEDIUM-CHAIN TRIGLYCERIDES (FRACTIONATED L) 837.60 lbs COCONUT OI
L-ARGININE 374.40 lbs CORN OIL 335.04 lbs MAGNESIUM CHLORIDE 152.47 lbs POTASSIUM C1:TRATE 152.12 lbs CALCIUM PHOSPHATE TRIBASIC (PREFERABLYMICRONIZED) 148.15 lbs CITRIC ACID 124.22 lbs SOY LECITHIN 83.76 lbs ASCORBIC ACID 38.36 lbs POTASSIUM PHOSPHATE DIBASIC 37.70 lbs CHOLINE CHLORICe 33.53 lbs IOTA CARRAGE:ENAN 25.50 lbs 459 POTASSIUM HYDROXIDE 25.26 lbs POTASSIUM CHLORIDE 14.62 lbs ULTRATRACE/T'RACE MINERAL PREMIX 14.41 lbs ZINC SULFP~TE 1338.91 gms FERROUS SULFATE 1287.79 gms MANGANESE SULFATE 353.72 gms CUPRIC SULFATE 190.75 gms SODIUM MOLYBDATE 9.64 gms CHROMIUM CHLORIDE 9.38 gms SODIUM SELENITE 3.65 gms CITRIC ACID 403.46 gms SUCROSE (Carrier) 2939.70 gms TAURINE 11.24 lbs L-CARNITINE 9.26 lbs WATER SOLUBLE VITAMIN PREMIX 2100.00 gms NIACINAMIDE 788.01 gms CALCIUM PANTOTHENATE 509.71 gms THIAMINE CHLORIDE HYDROCHLORIDE130.10 gms PYRIDOXINE HYDROCHLORIDE 125.24 gms RIBOFLAVIN 101.67 gms FOLIC ACID 17.65 gms BIOTIN 15.34 gms CYANOCOBAL~4MIN 0.35 gms DEXTROSE (Carrier) 411.93 gms OIL SOLUBLE 'VITAMIN PREMIX 1500.00 gms ALPHA-TOCOPHERYL ACETATE 1209.00 gms PHYLLOQUINONE 2.10 gms VITAMIN D3 0.27 gms COCONUT OII_ (carrier) 288.63 gms 30y BETA-CAROTENE 747.69 gms VITAMIN A PAI_MITATE 100.60 gms POTASSIUM IODIDE 4.20 gms 2.59: VITAMIN D3 1.76 gms ~ ~2~~~'~~
Table 1 presents the bill of materials for manufacturing 60,000 pounds of a liquid nutritional product according to the present invention.
INGREDIENT QUANTITY PER
60,000 LBS.
OF PRODUCT
WATER 42481.22 lbs HYDROLYZED t:ORNSTARCH 10517.95 lbs PARTIALLY HYDROLYZED SODIUM 2642.06 lbs LACTALBUMIN HYDROLYSATE 1093.71 lbs CANOLA OIL 837.60 lbs MEDIUM-CHAIN TRIGLYCERIDES (FRACTIONATED L) 837.60 lbs COCONUT OI
L-ARGININE 374.40 lbs CORN OIL 335.04 lbs MAGNESIUM CHLORIDE 152.47 lbs POTASSIUM C1:TRATE 152.12 lbs CALCIUM PHOSPHATE TRIBASIC (PREFERABLYMICRONIZED) 148.15 lbs CITRIC ACID 124.22 lbs SOY LECITHIN 83.76 lbs ASCORBIC ACID 38.36 lbs POTASSIUM PHOSPHATE DIBASIC 37.70 lbs CHOLINE CHLORICe 33.53 lbs IOTA CARRAGE:ENAN 25.50 lbs 459 POTASSIUM HYDROXIDE 25.26 lbs POTASSIUM CHLORIDE 14.62 lbs ULTRATRACE/T'RACE MINERAL PREMIX 14.41 lbs ZINC SULFP~TE 1338.91 gms FERROUS SULFATE 1287.79 gms MANGANESE SULFATE 353.72 gms CUPRIC SULFATE 190.75 gms SODIUM MOLYBDATE 9.64 gms CHROMIUM CHLORIDE 9.38 gms SODIUM SELENITE 3.65 gms CITRIC ACID 403.46 gms SUCROSE (Carrier) 2939.70 gms TAURINE 11.24 lbs L-CARNITINE 9.26 lbs WATER SOLUBLE VITAMIN PREMIX 2100.00 gms NIACINAMIDE 788.01 gms CALCIUM PANTOTHENATE 509.71 gms THIAMINE CHLORIDE HYDROCHLORIDE130.10 gms PYRIDOXINE HYDROCHLORIDE 125.24 gms RIBOFLAVIN 101.67 gms FOLIC ACID 17.65 gms BIOTIN 15.34 gms CYANOCOBAL~4MIN 0.35 gms DEXTROSE (Carrier) 411.93 gms OIL SOLUBLE 'VITAMIN PREMIX 1500.00 gms ALPHA-TOCOPHERYL ACETATE 1209.00 gms PHYLLOQUINONE 2.10 gms VITAMIN D3 0.27 gms COCONUT OII_ (carrier) 288.63 gms 30y BETA-CAROTENE 747.69 gms VITAMIN A PAI_MITATE 100.60 gms POTASSIUM IODIDE 4.20 gms 2.59: VITAMIN D3 1.76 gms ~ ~2~~~'~~
The liquid nutritional product of the present invention is manufactured by preparing three slurries which are then blended together, heat treated, standardized, packaged and sterilized. The process for manufacturing 60,000 pounds of the liquid nutritional product, using the bill of materials from Table 1, is described in detail below.
A carbohydrate/mineral slurry is prepared by first heating about 9,600 pounds of water to a temperature in the range of about 155' to 165'F with agitation. The ultratrace/trace mineral premix is added to the water and dissolvecl by agitating the resultant solution for at least one minute. The followings minerals are then added, in the order listed, with high agitation:
Potassium Iodide Potassium Citrate Magnesium Chloride Potassium Chloride Potassium Phosphate Dibasic Calcium Phosphate Tribasic The hydrolyzed cornstarch is then added to the resultant slurry.
The completed carbohydrate/mineral slurry is held with high agitation at a temperature in the range of about 155'F to 165'F for not longer than 12 hours until it is blended with the other slurries.
A protein-in-fat slurry is prepared by combining and heating the Medium Chain Triglycerides (fractionated coconut oil), corn oil and canola oil to a temperatui°e in the range of about 90'F to 110'F with agitation. The oil soluble vitamin premix, 2.5~ vitamin D3, vitamin A palmitate, and 30fe beta carotene are added to i:he slurry with agitation. The soy lecithin and carrageenan are then added to the slurry with agitation. (While iota-carrageenan is believed to be best when the product is to be packaged in metal. cans and terminally sterilized, i t i s wi thi n the scope of the i nventi on ~ to use other forms of carrageenan i f other packaging or sterilizing systems are used.) 409: of the partially hydrolyzef sodium caseinate is then added to the slurry with agitation. The completed protein-in-fat slurry is held under moderate agitation at a temperature in the range of about 90'F to 110'F for not longer than 12 hours until it is blended with the other slurries.
A protein-in-water slurry is prepared by first heating about 25,200 pounds of water to a temperature in the range of about 130'F to 150'F with agitation.
The slurry is maintained at a temperature in this range throughout the process of preparing the slurry. The L-arginine and citric acid are dumped directly into about half of the water with agitation, then the remaining water is added to the resultant solution. The remaining 60% of the partially hydrolyzed sodium caseinate is added to the L-arginine/citric acid solution and blended into a slurry using a mixing apparatus such as the two stage blender which is described in U. S. Patent 4, 850, 704, issued July 25, 1989, which teaches appropriate equipment for practicing, the p_=esent invention. The lactalbumin hydrolysate is ar~ded to the slurry using the above described mixing apparatus. It was discovered that adding the L-arginine and citric acid to water via the mixing apparaters of U.S. Patent 4,850,704 may cause manufacturing problems. The completed protein-in-water slurry is held under agitation at a temperature in the range of about 130° to 150°F for not longer than 2 hours before being blended with the other slurries. In large scale production it is desirable to prepare the protein-in-water slurry in several smaller batches to minimize the probability of microbial contamination of the slurry if it sits too lone before being blended with the other slurries.
The protein-in-~i:at and protein-in-water slurries are blended together w:it:h agitation and the resultant blended slurry is maintainE~d at a temperature in the range of about 130°F to 150°F. After waiting at least one minute the carbohydrate/mineral slurry is added to the blended slurry from the preceding step with agitation arid the resultant blended slurry is maintained at a temperature in the range of about: 130°F to 150°F. The vessel which 7a contained the care>ohydrate/mineral slurry should be rinsed with about 50 gallons of water and the rinse water should be added to t:he blended slurry.
After waiting a period of not less than one minute nor greater than two hours the blended slurry is subjected to deae:ration, Ultra-High-Temperature (UHT) treatment, and homogenization, as described below.
A. Use a positive pump for supplying the blended slurry for this procedure.
B. Heat the blended slurry to a temperature i.n the range of about 150°F to 160°F slurry by passing it through a heat exchanger.
C. Deaerate the blended slurry to 10-15 inches Hg.
D. Emulsify the blended slurry at 900-1,100 psi.
E. Heat the blended slurry to a temperature in the range of about 248°F to 252°F by passing it through a plate/coil heater with a hold time of approximately seconds.
F. UHT heat the blended slurry to a temperature :in the range of about 292°F to 296°F with a hold time of approximately 5 seconds.
G. Reduce the temperature of the blended slurry to be in the range of: about 248°F to 252°F by passing it through a flash. cooler.
A carbohydrate/mineral slurry is prepared by first heating about 9,600 pounds of water to a temperature in the range of about 155' to 165'F with agitation. The ultratrace/trace mineral premix is added to the water and dissolvecl by agitating the resultant solution for at least one minute. The followings minerals are then added, in the order listed, with high agitation:
Potassium Iodide Potassium Citrate Magnesium Chloride Potassium Chloride Potassium Phosphate Dibasic Calcium Phosphate Tribasic The hydrolyzed cornstarch is then added to the resultant slurry.
The completed carbohydrate/mineral slurry is held with high agitation at a temperature in the range of about 155'F to 165'F for not longer than 12 hours until it is blended with the other slurries.
A protein-in-fat slurry is prepared by combining and heating the Medium Chain Triglycerides (fractionated coconut oil), corn oil and canola oil to a temperatui°e in the range of about 90'F to 110'F with agitation. The oil soluble vitamin premix, 2.5~ vitamin D3, vitamin A palmitate, and 30fe beta carotene are added to i:he slurry with agitation. The soy lecithin and carrageenan are then added to the slurry with agitation. (While iota-carrageenan is believed to be best when the product is to be packaged in metal. cans and terminally sterilized, i t i s wi thi n the scope of the i nventi on ~ to use other forms of carrageenan i f other packaging or sterilizing systems are used.) 409: of the partially hydrolyzef sodium caseinate is then added to the slurry with agitation. The completed protein-in-fat slurry is held under moderate agitation at a temperature in the range of about 90'F to 110'F for not longer than 12 hours until it is blended with the other slurries.
A protein-in-water slurry is prepared by first heating about 25,200 pounds of water to a temperature in the range of about 130'F to 150'F with agitation.
The slurry is maintained at a temperature in this range throughout the process of preparing the slurry. The L-arginine and citric acid are dumped directly into about half of the water with agitation, then the remaining water is added to the resultant solution. The remaining 60% of the partially hydrolyzed sodium caseinate is added to the L-arginine/citric acid solution and blended into a slurry using a mixing apparatus such as the two stage blender which is described in U. S. Patent 4, 850, 704, issued July 25, 1989, which teaches appropriate equipment for practicing, the p_=esent invention. The lactalbumin hydrolysate is ar~ded to the slurry using the above described mixing apparatus. It was discovered that adding the L-arginine and citric acid to water via the mixing apparaters of U.S. Patent 4,850,704 may cause manufacturing problems. The completed protein-in-water slurry is held under agitation at a temperature in the range of about 130° to 150°F for not longer than 2 hours before being blended with the other slurries. In large scale production it is desirable to prepare the protein-in-water slurry in several smaller batches to minimize the probability of microbial contamination of the slurry if it sits too lone before being blended with the other slurries.
The protein-in-~i:at and protein-in-water slurries are blended together w:it:h agitation and the resultant blended slurry is maintainE~d at a temperature in the range of about 130°F to 150°F. After waiting at least one minute the carbohydrate/mineral slurry is added to the blended slurry from the preceding step with agitation arid the resultant blended slurry is maintained at a temperature in the range of about: 130°F to 150°F. The vessel which 7a contained the care>ohydrate/mineral slurry should be rinsed with about 50 gallons of water and the rinse water should be added to t:he blended slurry.
After waiting a period of not less than one minute nor greater than two hours the blended slurry is subjected to deae:ration, Ultra-High-Temperature (UHT) treatment, and homogenization, as described below.
A. Use a positive pump for supplying the blended slurry for this procedure.
B. Heat the blended slurry to a temperature i.n the range of about 150°F to 160°F slurry by passing it through a heat exchanger.
C. Deaerate the blended slurry to 10-15 inches Hg.
D. Emulsify the blended slurry at 900-1,100 psi.
E. Heat the blended slurry to a temperature in the range of about 248°F to 252°F by passing it through a plate/coil heater with a hold time of approximately seconds.
F. UHT heat the blended slurry to a temperature :in the range of about 292°F to 296°F with a hold time of approximately 5 seconds.
G. Reduce the temperature of the blended slurry to be in the range of: about 248°F to 252°F by passing it through a flash. cooler.
H. Reduce the temperature of the blended slurry to be in the range of about 165~F to 185~F by passing it through a plate/coil cooler.
I. Homogenize the blended slurry at about 3,900 to 4,100 psi.
J. Pass the blended slurry through a hold tube for at least 16 seconds at a temperature in the range of about 165~F to 185~F.
K. Cool the blended slurry to a temperature in the range of about 34~F
to 44~F by passing it through a large heat exchanger.
L. Store the blended slurry at a temperature in the range of about 34~F
to 44~F, preferably with agitation.
Two vitamin solutions are prepared separately and then added to the blended slurry. The first vitamin solution is prepared by heating 90 gallons of water to a temperature in the range of about 110~F to 150~F with agitation, and thereafter adding the taurine and water soluble vitamin premix to the water.
The ser_ond vitamin solution is prepared by providing 90 gallons of room temperature water and adding the choline chloride, ascorbic acid, L-carnitine and 25.26 pounds of 45% potassium hydroxide to the water with agitation. The two vitamin solutions are then added to the blended slurry with agitation within one hour after the vitamin solutions are prepared. If necessary, diluted potassium hydroxide is added to the blended slurry such that the product will have a pH in the range of 6.4 to 7.O after sterilization. The completed product is then placed in suitable containers and subjected to sterilization.
The nutritional profile of the liquid nutritional product of the present invention is presented in Table 2.
~~ '' ' ~ r ;; F
l.y ~ :,n s i a ~ d' N ~D O O O sT et tf1 1p a C~ f~ O O O c1 10 CO O O t~ t~ t~ O O O O
. . vo o~ o vo ~ v c-wn , r~ I . . ..a c.
r OD V' t0 N . . . N 01 10 ~D V' !7 t1 f'1 P1 t0 f~ ~D f1 I~ N .-1 O I~ 10 01 tf1 tD CO
N N lf1 N N N f~ !L7 l"1 ~ ~
,.~ r./ rl O W P1 r1 d, ~-1 r-1 rl W-1 r1 , 10 f'1 CO
ro A ..., dP dP ~ d dP o\ dP dP dP dP dP dP
* 00 * *
W *
d \ N dP I~ dP * dP
*
e ro o ~"~
P o CO
* * 10 t0 t0 In * dP 0 10 * * * * *
* CO * * .
1 .
1 *
-i *
* *
r r r ~
r * . . . . * ,..i *
~
~
' l CO * * .
r1 r O c 1 *
c 7 c 1 ~-r 1 * c 7 O * * * O O O O * N O O
~' N f7 ("7 P1 N N N N P1 N
a\
N
ro o W to O f'1 GO f'l N CO N CO c'7 N N O -..I
m I~ f'1 ~ G~ N ~ O O O ~O tp "' ' ~
>
. . . ~ f If1 1 1 , f N ~
N7 O O ~ 10 1~ to rl rl rl .-i 1(1 CO N ~ O 00 i l0 ~
~ r ',.yD H ~ ~ N C f'1 N N N O . . r-1 N f'1 f"1 f'1 1 Q' N O O O
"
r '[f f 1 t0 N1 e-) O ~ f'1 G
N ro G
la H U dP dP dP eW dP dP dP dP dP dW dP dP dP dP dP dP dP dP
dP
* * * * * * *
.sG O O O O O O O O O O O O O O O O O O O
O * * * * O O !l7 * O tf~ IL1 111 tf1 It1 In * tl7 If1 ro * * * O O O O * O In O * * * * *
o N ~-i ri tf1 rl rl rI e-1 e~ '1 rl rl e-i e-i e~-1 rW V
-1 v-i rl R
d ~ 13 N
O 'O
ov~l~' o w o0o0o m rl , , 0 0 ooc~ 00 0o 00 0000 -I o wo ui o InOOOOO coo Id ~ '-i O O O O lI1 O In tf1 N O ~l1 lL7 tI7 h0 cn a' c0 r1 '-1 N O 01 O O N H I~ W
' ' ' ' x ~ d N N f f 1 0~
d ,.~ N r-i r1 n-1 ~ ~ N ~-1 ri ra '-i ~,~ C' N
H
., >
.
~7 ':J
U
N
t0 _ N
~
H .,..I
O
V .i~
R
.p N
..1 .N
a H H U U O
~ ~
CT
U ~ U ~
+~ ~ ~ s ~ ~ ro ~ >r tr o~ tr ~
C1 U ~~ N ~ ~ ~E ~ U U O
N
I. Homogenize the blended slurry at about 3,900 to 4,100 psi.
J. Pass the blended slurry through a hold tube for at least 16 seconds at a temperature in the range of about 165~F to 185~F.
K. Cool the blended slurry to a temperature in the range of about 34~F
to 44~F by passing it through a large heat exchanger.
L. Store the blended slurry at a temperature in the range of about 34~F
to 44~F, preferably with agitation.
Two vitamin solutions are prepared separately and then added to the blended slurry. The first vitamin solution is prepared by heating 90 gallons of water to a temperature in the range of about 110~F to 150~F with agitation, and thereafter adding the taurine and water soluble vitamin premix to the water.
The ser_ond vitamin solution is prepared by providing 90 gallons of room temperature water and adding the choline chloride, ascorbic acid, L-carnitine and 25.26 pounds of 45% potassium hydroxide to the water with agitation. The two vitamin solutions are then added to the blended slurry with agitation within one hour after the vitamin solutions are prepared. If necessary, diluted potassium hydroxide is added to the blended slurry such that the product will have a pH in the range of 6.4 to 7.O after sterilization. The completed product is then placed in suitable containers and subjected to sterilization.
The nutritional profile of the liquid nutritional product of the present invention is presented in Table 2.
~~ '' ' ~ r ;; F
l.y ~ :,n s i a ~ d' N ~D O O O sT et tf1 1p a C~ f~ O O O c1 10 CO O O t~ t~ t~ O O O O
. . vo o~ o vo ~ v c-wn , r~ I . . ..a c.
r OD V' t0 N . . . N 01 10 ~D V' !7 t1 f'1 P1 t0 f~ ~D f1 I~ N .-1 O I~ 10 01 tf1 tD CO
N N lf1 N N N f~ !L7 l"1 ~ ~
,.~ r./ rl O W P1 r1 d, ~-1 r-1 rl W-1 r1 , 10 f'1 CO
ro A ..., dP dP ~ d dP o\ dP dP dP dP dP dP
* 00 * *
W *
d \ N dP I~ dP * dP
*
e ro o ~"~
P o CO
* * 10 t0 t0 In * dP 0 10 * * * * *
* CO * * .
1 .
1 *
-i *
* *
r r r ~
r * . . . . * ,..i *
~
~
' l CO * * .
r1 r O c 1 *
c 7 c 1 ~-r 1 * c 7 O * * * O O O O * N O O
~' N f7 ("7 P1 N N N N P1 N
a\
N
ro o W to O f'1 GO f'l N CO N CO c'7 N N O -..I
m I~ f'1 ~ G~ N ~ O O O ~O tp "' ' ~
>
. . . ~ f If1 1 1 , f N ~
N7 O O ~ 10 1~ to rl rl rl .-i 1(1 CO N ~ O 00 i l0 ~
~ r ',.yD H ~ ~ N C f'1 N N N O . . r-1 N f'1 f"1 f'1 1 Q' N O O O
"
r '[f f 1 t0 N1 e-) O ~ f'1 G
N ro G
la H U dP dP dP eW dP dP dP dP dP dW dP dP dP dP dP dP dP dP
dP
* * * * * * *
.sG O O O O O O O O O O O O O O O O O O O
O * * * * O O !l7 * O tf~ IL1 111 tf1 It1 In * tl7 If1 ro * * * O O O O * O In O * * * * *
o N ~-i ri tf1 rl rl rI e-1 e~ '1 rl rl e-i e-i e~-1 rW V
-1 v-i rl R
d ~ 13 N
O 'O
ov~l~' o w o0o0o m rl , , 0 0 ooc~ 00 0o 00 0000 -I o wo ui o InOOOOO coo Id ~ '-i O O O O lI1 O In tf1 N O ~l1 lL7 tI7 h0 cn a' c0 r1 '-1 N O 01 O O N H I~ W
' ' ' ' x ~ d N N f f 1 0~
d ,.~ N r-i r1 n-1 ~ ~ N ~-1 ri ra '-i ~,~ C' N
H
., >
.
~7 ':J
U
N
t0 _ N
~
H .,..I
O
V .i~
R
.p N
..1 .N
a H H U U O
~ ~
CT
U ~ U ~
+~ ~ ~ s ~ ~ ro ~ >r tr o~ tr ~
C1 U ~~ N ~ ~ ~E ~ U U O
N
11 R', O W v0 ri ~ b~ U ~ ~ U1 b~ ,F, ~ O C~ ,r"
O
1T ~ 'Cf C I I LT ~ U .~ ~ ~ O U b~ ~ G ~ b la a ~ !; a4 U -a r1 fa a1 ~ ~ C ~ ~ O ~ E N ~ ~ ~ -.1 H ~ 'L3 !T .~ -~ U > ~ Gl O N f.t ~ N b~ b~ ~ ~ ~ 11 D
.-1 Z 1~ ?, ~ ~ & ~ ~ a O c0 O ~ ~ N x -.~ 't3 ~ O -.a . ~ C~
~ ~ ~ O d ..i O U
W .~ ~ y' ~ rl f0 ro 1 -.-1 .1 .-1 .i .1 ~ ~ .f., ~ ~ llWrifn ~ .G N G) C ~.1 .1 .i b ~ ~ O
H ~D O it ~ 1~ ~..~ )= E; U ~ W ~ ~ ..1 ..-r .a p ~ Ul b f-i .1 L1 N ~ ro N ~ C E .t7 i-~ .i H
P4 ~ -,L7 N ro a -~ ro ro - ro O ro ro U .-r ~ i~ -a ro O U Vl C ~I b~ p, U G N O ?~ ro lr o ~ ~ ~ ~ > ~ ~ ~ .-~ .~ .cm y ro o 0 o b ~ .-I ,-a o tr~ Tr c n. c o ~I N .-r v o >a ro ro ro .~ .~ .~ o ~ ~r .~ .~ .~ ~ ~ ro o o .c ro .a ro o ro o -~I N a~ .c o I ro C4 4r U 3 'J H H ,7 ~~ G4 [~ R,' 'J 'J ,~ U C7 LL Cn *
W U U Oa ,' H ,'~ U N H fn U ,'>~ a Ea '-I
~~~~~)~~
The body's stores of protein are in a constant state of breakdown and synthesis. Tissues differ in their rate of protein turnover, from rapid (intestinal mucosal cells) to relatively slow (muscle). The daily amount of protein turnover far exceeds dietary intake, indicating a great conservation of amino acids. However, many metabolic nitrogenous products, such as urea, are lost daily. These losses contribute to a need for nitrogen in the form of dispensable (nonessential) amino acids in addition to the need for indispensable (essential) amino acids for protein components of tissues.
Dietary proteins that provide a balanced amino acid profile and are biologically available are referred to as high-quality proteins. Protein requirements cannot be totally separated from energy requirements because protein is used as an energy substrate and not for tissue synthesis in the absence of adequate calories.
That protein deficiency rarely occurs independent of calorie malnutrition demonstrates the interrelationship of protein and energy needs. Protein deficiency is usually exhibited in the form of protein energy malnutrition. Both anabolic and catabolic processes are accelerated after severe trauma, although catabolism predominates. Accelerated catabolism after trauma provides substrate through the breakdown of muscle tissue. This mechanism provides amino acids for synthesis of proteins involved in immunologic response and tissue repair. The hypermetabolism that occurs after injury often makes meeting the patient's caloric needs difficult. In the nutritional product of the present invention the caloric density is about 1.2 to 1.5 kcal/ml, preferably about 1.3 kcal/mL and the total calorie to nitrogen ratio is about 112:1 to about 145:1, most preferably about 115:1 to about 135:1. The advantage of this caloric density is that a smaller volume of the product is required to meet the patient's needs, and many trauma or surgical patients have restricted fluid intakes and/or volume intolerant. Volume intolerance is not uncommon, for example, young adult males have normally high metabolic rates which may be accelerated even further by trauma so that a large number of calories are required daily. If the caloric density (kcal/ml) is too low the volume of product required may result WO 93/16595 '~ '~ " '~ v'~ ~' PCT/US93/01100 ~ .y ~~ ~_) v !
in bloating and/or difficulty feeding a sufficient volume through a feeding tube. One of the problems solved by the nutritional product of the present invention is not simply providing a particular caloric density, but a particular caloric density in which about 18-24%, most preferably about 20.5% of the calories are provided by proteins; about 20-30%, preferably about 23-27% and most preferably about 24-2G% of the calories are provided by lipids: and about 46 to 62%, preferably 50-58%, most preferably about 52-56% of the calories are provided by carbohydrates. Current U.S. guidelines for healthy persons state that about 15% of calories should be contributed by protein, less than 30% from fat and the remainder by carbohydrate. The nutritional invention provides a higher level of a protein and the protein is from a blend which provides a balanced amino acid profile. The protein level is not as high as some commercial formulas so as to avoid potential problems.
When protein supplies energy, only the carbon skeleton of the constituent amino acids are used, whereas the nitrogen is excreted through the urine. The negative nitrogen balance observed in critically ill patients may be attributed to an inadequate caloric intake, rather than an insufficient protein intake. Accelerated catabolism and large urinary nitrogen losses after trauma may be obligatory. It is uncertain whether providing large amounts of protein can alter catabolism or nitrogen losses after injury or illness. In addition, some mobilization of protein and calcium results from bed rest.
Disuse atrophy contributes to the muscle wasting and negative nitrogen balance frequently observed in the immobilized trauma patient.
In the nutritional product of the invention the protein system comprises lactalbumin hydrolysate, partially hydrolyzed sodium caseinate and L-arginine. The (AOAC) Association of Official Analytical Chemists protein efficiency ratio assays of the nutritional product of the present invention indicated that the product has good quality protein. About 20-35%, preferably about 20-30% and most preferably about 22-27% by weight of the protein system comprises lactalbumin hydrolysate (a suitable commercially available commodity is Alatal"'.817 which is distributed by New Zealand Milk Products); about 60-70%, lz preferably about 62-68% and mast preferably about 64-66% by weight of the protein system comprises partially hydrolyzed sodium caseinate; (a suitable commercially available commodity is Alanate'" 166 which is distributed by New Zealand Milk Products; and about 8-14%, preferably about 8-12%, and most preferably about 9-11% by weight of the protein system comprises L-arginine. Preferably the L-arginine is not in the form of arginine HCL or a DL-arginine mix because only the L-arginine provides the desired effect on the patient. A liquid nutritional product according to the present invention provides about 6.9-11.1 grams of arginine per 1,500 kcal, with 1,500 kcal being the nutrient base provided to the average patient in a 24 hour period. It is further considered to be critical to the practice of the invention that the supplemental L-arginine (excluding the L-arginine that may be inherent in other ingredients) provide about 1-3% of the total calories in the nutritional product.
One of the nutritional advantages of the lactalbumin hydrolysate in the protein system is that it provides some peptides to the patient. Evidence supports the existence of separate and noncompeting,carrier-mediated transport systems for free amino acids and for small peptides in the gastrointestinal tract. Uptake of peptides by the small intestine is nutritionally significant. Studies indicate that peptides are absorbed more rapidly than free-form amino acids. The physiologic importance of these separate transport systems is probably accentuated during malnutrition and other pathologic conditions because amino acid uptake from peptides is affected less than uptake of free amino acids.
Whey proteins such as lactalbumin have a high biologic value and contain an adequate supply of sulfur amino acids.
Lactalbumin proteins have been reported to produce unique effects. For example, diets containing lactalbumin produced an enhanced immune response in mice. In a published report a comparison to mice fed a control diet, those fed lactalbumin showed significant increases in immunologic response to antigen, thymic weight, and cellularity and level of a complement protein. Partially hydrolyzed lactalbumin may be absorbed better and promote weight gain more effectively than either intact WO 93/16595 ~ ~ -~a ~ ~~ ~ ~ PCT/US93/01100 1~
protein or free amino acids.
Arginine can have several physiologic effects. For example, accelerated wound healing and nitrogen retention after injury have been attributed to the feeding of arginine. The effects on wound healing may be due to increased synthesis of collagen in wounds. Published reports have indicated that rats fed diets supplemented with both arginine (2.4%) and glycine (1%) deposited more hydroxyproline (a component of collagen) in wounds that were healing when compared to animals fed control diets. Published studies have examined the effects of dietary argini.ne on cells of the immune system, such as T-lymphocytes and natural killer cells. Supplemental arginine may enhance immune function through increases in thymic weight and enhanced thymoc;yte and peripheral blood lymphocyte response to mitogens.
Similarly, published reports have indicated that surgical patients whose diets were supplemented with arginine (25g/day) exhibited increased T-lymphocyte activation compared with a group fed glycine. Another published study found that dietary L-arginine was important for lymphokine-activated killer cell activity. Other published studies have reported that diets providing 6% of total calories as arginine HCL were associated with an increased mortality in animal models of sepsis. The product of the present invention has 1-3% of the total calories provided by L-arginine.
The amino acid profile of the nutritional product of the present invention is presented in Table 3, and meets the standard for high biological protein set by the U.S. RDA
Committee.
AMINO ACID g/100g protein INDISPENSABLE TARGET PREFERRED
RANGE
Histidine 2.1 1:7 2.4 -Isoleucine 4.2 4:1 5.1 -Leucine 9.0 7:9 12.5 -Lysine 7.1 5:5 9.4 -Methionine 2.3 2.1 2.9 -Phenylalanine 4.1 3.5 4.9 -Threonine 4.0 3.9 5.3 -Tryptophan 1.2 1.1 2.0 -Valine 5.0 4.8 6.5 -DISPENSABLE
Alanine 3.3 2.9 4.4 -Arginine (Includes 12.1 9.0 14.0 -inherent arginine) Aspartic Acid 7.5 6.5 10.00 -Cystine 1.1 0.7 2.2 -Glutamic Acid 18.3 17.5 - 20.5 Glycine 1.5 1.5 1.9 -Proline 8.0 6.5 9.0 -Serine 4.9 4.8 5.1 -Tyrosine 4.2 3.7 5.1 -14a Carbohydrate is an important energy source for the injured individual as it is readily absorbed and utilized. It is the preferred fuel for the brain and red blood cells. The hyperglycemia of trauma is attributed to alterations in thE= hormonal milieu. This causes an increased rate, of gluconeogenesis in the presence of elevated glulcocorti.coid, catecholamine, insulin and a hyperglycemic state. The carbohydrate in the product of the present invention is preferably provided primarily by hydrolyzed corn starch. A commercially available hydrolyzed corn starch commodity is Maltrin 100 (Trade-mark) which is distributed by Grain Processing Corporation of Muscatine, Iowa, U.S.A.
Although the formulation presented in Table .L does not contain dietary fiber, it is considered to be within the scope of the ~>resent invention to employ dietary fiber in the nutritional product disclosed herein.
Numerous types of dietary fibers are currently available.
Basically, dietary fiber passes through the small intestine undigested by enzymes and is a kind of natural and necessary laxative. As used herein and in the claims, dietary fiber is understood to be all of the components of food that are nct. broken down by enzymes in the human digestive tract to produce small molecular compounds which are then absorbed into the bloodstream. A
nutritional product according to the invention has been made containing gum arabic or a source of dietary fiber.
Another possible fiber sources that may be employed in the product is thc~ blend of dietary fibers which is taught in commonly assigned U.S. Patent 5,085,883 issued February 4, 1992.
Lipids provide energy and essential fatty acids and enhance absorption of the fat soluble vitamins. The type of lipid consumed affects many physiological parameters such as plasma lipid profile, membrane lipid composition and synthesis of mediators of the immune response such as prostaglandins and i~:hromboxanes. Fat may be anappropriate fuel source for t:he hyperglycemic patient if peripheral tissues are insulin insensitive. The lipid system in the product of the pr~=sent invention preferably comprises canola oil, medium chain triglycerides (fractionated coconut oil) and corn oil. Canola oil provides alpha linolenic acid, l.inoleic acid and oleic acid. It is relatively low in saturated fat. The omega three-fatty acid provided by canola oil may have beneficial effects on the immune system, mediated through changes in the synthesis of prostaglandin. Corn oil is a source of Linoleic acid which is an essential fatty acid. Medium 15a chain triglyceride~; are a readily absorbed source of energy and are useful in meeting the caloric. need of stressed patients.
In a nutritional product according to the embodiment set forth in Table 1 the lipid system comprises by weight: (a) about 35-550, preferably about 35-45%, and most preferably about 38-42% canola oil; (b) about 30-50%, preferably about 35-45%, and most preferably about 38-42% medium chairs triglycerides (fractionated coconut oil: and (c) about 5--35-1, preferably about 10-30%, most WO 93/16595 ~ PCT/US93/0~'~10 preferably about 15-25% corn oil. It is believed, however, that a satisfactory nutritional product according to the present invention may be made having a lipid system comprising about 40%
medium chain triglycerides and about 60% canola oil. The lipid system provides a ratio of linoleic to alpha linolenic acid in the range of about 3.5:1 to about 5.5:1. The nutritional product of the present invention has about 4-5% of the total calories provided by the essential fatty acid linoleic acid.
It has been recommended in the prior art that critically ill patients be provided with this level of linoleic acid.
Preferably the fatty acid profile provided to the nutritional product is that set forth in Table 4.
WO 93/16595 PCf/US93/01100 ,~ : ~ ,-, n x7 .,~
fr; ~~ r 1,, _ FATTY ACID % Total Fatty Acids TARGET PREFERRED RANGE
Linoleic (18:2e6) 21 19 - 24 a-Linolenic (18:33) 4.5 3.5 - 12 NONEHBENTIAL
Caprylic (8:0) 23 18 - 26 Capric (10:0) 10.3 10.2 - 15.5 Lauric (12:0) 0.1 trace - 0.4 Myristic (14:0) 0.3 trace - 0.7 Palmitic (16:0) 5.0 4.0 - 7.2 Stearic (18:0) 1.7 trace - 1.9 Oleic (18:1~r9) 31 20 - 45 Arachidic (20:0) 0.4 trace - 0.6 Eiosenoic (20:19) 0.4 trace - 0.6 Others 2.3 trace -10 There is evidence that vitamin A may reverse some of the immunosuppression which occurs following thermal injury or radiation injury; therefore, additional vitamin A for trauma patients may be beneficial. In particular, the cellular immune system may be responsive to vitamin A as measured by enhanced mixed lymphocyte reactions in burned animals given supplemental vitamin A palmitate. One published study examined the effects of vitamin A on impaired wound healing which accompanies radiation. Supplemental vitamin A administered prior to or after radiation or injury prevented the impaired wound healing, gastric ulceration and thymic involution which is typically observed. Beta carotene does not have the toxicity problems of vitamin A and may be the preferred form to add supplemental retinol equivalents to the diet. Deta carotene itself may enhance immune system Function and functions as an antioxidant.
The nutritional product of the present invention contains both vitamin A and beta carotene.
WO 93/16595 PCT/US93/O11(10 Vitamin E acts as an antioxidant and plays a role in the immune system, and is present in the nutritional product at a level of at least 45 IU per 1,500 kcals.
Taurine (p-aminoethanesulfonic acid) is involved in a wide variety of metabolic processes, including those of the central nervous system. It is involved in the conjugation of bile acids, helps regulate the aggregation of platelets, and aids in the function of neutrophils. Synthesized via cysteine, taurine is classified as a sulfur-containing amino acid. It is considered nonessential for humans under normal physiologic circumstances, although a decline in serum taurine concentrations suggests that taurine supplementation is needed in the postinjury state. A published study of severely burned patients indicated that the metabolism of methionine and cysteine may be altered after injury.
Carnitine is required metabolically to transfer long-chain fatty acids into the mitochondria for energy production.
Carnitine is present in food, including meats and dairy products, and typical mixed diets provide 0.18 to 319 mg of carnitine/day. Published clinical trials have indicated that the excretion of carnitine increases after injury, and carnitine deficiency during antibiotic therapy has been reported. These results indicate that the supply of carnitine may be limited under certain circumstances and, therefore, should be supplied to trauma and major surgery patients.
Both taurine and carnitine are provided in a preferred embodiment of the present invention. The recommended intake of zinc is l5mg/day for a healthy adult, and inadequate zinc intake by "healthy" people is not uncommon. An inadequate intake of zinc is associated with skin lesions, poor wound healing and immunodeficiency characterized by thymic atrophy. Alterations in zinc metabolism occur after trauma. For example, sepsis is associated with a decreased serum zinc level and an accumulation of zinc within the liver. The product of the present invention provides at least 100% of the U.S. RUA of zinc. The product of the invention contains vitamin C and the B vitamins in amounts greater than the U.S.RDA for an amount of product sufficient to provide 1500 kcal to insure adequate for hypermetabolic patients.
WO 93/ 16595 '> y y ~ ~ '~ ~ PCT/US93/01100 ~s~~
The nutritional product of the present invention has a moderate osmolality of about 425 Mosm/ky water, even though the product contains partially hydrolyzed proteins and has a greater caloric density as compared to prior art formulations.
Formulations high in osmolarity may increase the risk of osmotic diarrhea. The nutritional product of the present invention has a viscosity of not greater than 55 cps, preferably about 25-45 cps, which is wnsistent with good tube feeding characteristics.
The nutritionz: :roduct of the present invention is intended primarily to Y: ~ed to a patient via a feeding tube in a manner which is well own in the art. However, it is considered to be within the sc: of this invention to add a flavoring system to allow oral feed«.,~.
O
1T ~ 'Cf C I I LT ~ U .~ ~ ~ O U b~ ~ G ~ b la a ~ !; a4 U -a r1 fa a1 ~ ~ C ~ ~ O ~ E N ~ ~ ~ -.1 H ~ 'L3 !T .~ -~ U > ~ Gl O N f.t ~ N b~ b~ ~ ~ ~ 11 D
.-1 Z 1~ ?, ~ ~ & ~ ~ a O c0 O ~ ~ N x -.~ 't3 ~ O -.a . ~ C~
~ ~ ~ O d ..i O U
W .~ ~ y' ~ rl f0 ro 1 -.-1 .1 .-1 .i .1 ~ ~ .f., ~ ~ llWrifn ~ .G N G) C ~.1 .1 .i b ~ ~ O
H ~D O it ~ 1~ ~..~ )= E; U ~ W ~ ~ ..1 ..-r .a p ~ Ul b f-i .1 L1 N ~ ro N ~ C E .t7 i-~ .i H
P4 ~ -,L7 N ro a -~ ro ro - ro O ro ro U .-r ~ i~ -a ro O U Vl C ~I b~ p, U G N O ?~ ro lr o ~ ~ ~ ~ > ~ ~ ~ .-~ .~ .cm y ro o 0 o b ~ .-I ,-a o tr~ Tr c n. c o ~I N .-r v o >a ro ro ro .~ .~ .~ o ~ ~r .~ .~ .~ ~ ~ ro o o .c ro .a ro o ro o -~I N a~ .c o I ro C4 4r U 3 'J H H ,7 ~~ G4 [~ R,' 'J 'J ,~ U C7 LL Cn *
W U U Oa ,' H ,'~ U N H fn U ,'>~ a Ea '-I
~~~~~)~~
The body's stores of protein are in a constant state of breakdown and synthesis. Tissues differ in their rate of protein turnover, from rapid (intestinal mucosal cells) to relatively slow (muscle). The daily amount of protein turnover far exceeds dietary intake, indicating a great conservation of amino acids. However, many metabolic nitrogenous products, such as urea, are lost daily. These losses contribute to a need for nitrogen in the form of dispensable (nonessential) amino acids in addition to the need for indispensable (essential) amino acids for protein components of tissues.
Dietary proteins that provide a balanced amino acid profile and are biologically available are referred to as high-quality proteins. Protein requirements cannot be totally separated from energy requirements because protein is used as an energy substrate and not for tissue synthesis in the absence of adequate calories.
That protein deficiency rarely occurs independent of calorie malnutrition demonstrates the interrelationship of protein and energy needs. Protein deficiency is usually exhibited in the form of protein energy malnutrition. Both anabolic and catabolic processes are accelerated after severe trauma, although catabolism predominates. Accelerated catabolism after trauma provides substrate through the breakdown of muscle tissue. This mechanism provides amino acids for synthesis of proteins involved in immunologic response and tissue repair. The hypermetabolism that occurs after injury often makes meeting the patient's caloric needs difficult. In the nutritional product of the present invention the caloric density is about 1.2 to 1.5 kcal/ml, preferably about 1.3 kcal/mL and the total calorie to nitrogen ratio is about 112:1 to about 145:1, most preferably about 115:1 to about 135:1. The advantage of this caloric density is that a smaller volume of the product is required to meet the patient's needs, and many trauma or surgical patients have restricted fluid intakes and/or volume intolerant. Volume intolerance is not uncommon, for example, young adult males have normally high metabolic rates which may be accelerated even further by trauma so that a large number of calories are required daily. If the caloric density (kcal/ml) is too low the volume of product required may result WO 93/16595 '~ '~ " '~ v'~ ~' PCT/US93/01100 ~ .y ~~ ~_) v !
in bloating and/or difficulty feeding a sufficient volume through a feeding tube. One of the problems solved by the nutritional product of the present invention is not simply providing a particular caloric density, but a particular caloric density in which about 18-24%, most preferably about 20.5% of the calories are provided by proteins; about 20-30%, preferably about 23-27% and most preferably about 24-2G% of the calories are provided by lipids: and about 46 to 62%, preferably 50-58%, most preferably about 52-56% of the calories are provided by carbohydrates. Current U.S. guidelines for healthy persons state that about 15% of calories should be contributed by protein, less than 30% from fat and the remainder by carbohydrate. The nutritional invention provides a higher level of a protein and the protein is from a blend which provides a balanced amino acid profile. The protein level is not as high as some commercial formulas so as to avoid potential problems.
When protein supplies energy, only the carbon skeleton of the constituent amino acids are used, whereas the nitrogen is excreted through the urine. The negative nitrogen balance observed in critically ill patients may be attributed to an inadequate caloric intake, rather than an insufficient protein intake. Accelerated catabolism and large urinary nitrogen losses after trauma may be obligatory. It is uncertain whether providing large amounts of protein can alter catabolism or nitrogen losses after injury or illness. In addition, some mobilization of protein and calcium results from bed rest.
Disuse atrophy contributes to the muscle wasting and negative nitrogen balance frequently observed in the immobilized trauma patient.
In the nutritional product of the invention the protein system comprises lactalbumin hydrolysate, partially hydrolyzed sodium caseinate and L-arginine. The (AOAC) Association of Official Analytical Chemists protein efficiency ratio assays of the nutritional product of the present invention indicated that the product has good quality protein. About 20-35%, preferably about 20-30% and most preferably about 22-27% by weight of the protein system comprises lactalbumin hydrolysate (a suitable commercially available commodity is Alatal"'.817 which is distributed by New Zealand Milk Products); about 60-70%, lz preferably about 62-68% and mast preferably about 64-66% by weight of the protein system comprises partially hydrolyzed sodium caseinate; (a suitable commercially available commodity is Alanate'" 166 which is distributed by New Zealand Milk Products; and about 8-14%, preferably about 8-12%, and most preferably about 9-11% by weight of the protein system comprises L-arginine. Preferably the L-arginine is not in the form of arginine HCL or a DL-arginine mix because only the L-arginine provides the desired effect on the patient. A liquid nutritional product according to the present invention provides about 6.9-11.1 grams of arginine per 1,500 kcal, with 1,500 kcal being the nutrient base provided to the average patient in a 24 hour period. It is further considered to be critical to the practice of the invention that the supplemental L-arginine (excluding the L-arginine that may be inherent in other ingredients) provide about 1-3% of the total calories in the nutritional product.
One of the nutritional advantages of the lactalbumin hydrolysate in the protein system is that it provides some peptides to the patient. Evidence supports the existence of separate and noncompeting,carrier-mediated transport systems for free amino acids and for small peptides in the gastrointestinal tract. Uptake of peptides by the small intestine is nutritionally significant. Studies indicate that peptides are absorbed more rapidly than free-form amino acids. The physiologic importance of these separate transport systems is probably accentuated during malnutrition and other pathologic conditions because amino acid uptake from peptides is affected less than uptake of free amino acids.
Whey proteins such as lactalbumin have a high biologic value and contain an adequate supply of sulfur amino acids.
Lactalbumin proteins have been reported to produce unique effects. For example, diets containing lactalbumin produced an enhanced immune response in mice. In a published report a comparison to mice fed a control diet, those fed lactalbumin showed significant increases in immunologic response to antigen, thymic weight, and cellularity and level of a complement protein. Partially hydrolyzed lactalbumin may be absorbed better and promote weight gain more effectively than either intact WO 93/16595 ~ ~ -~a ~ ~~ ~ ~ PCT/US93/01100 1~
protein or free amino acids.
Arginine can have several physiologic effects. For example, accelerated wound healing and nitrogen retention after injury have been attributed to the feeding of arginine. The effects on wound healing may be due to increased synthesis of collagen in wounds. Published reports have indicated that rats fed diets supplemented with both arginine (2.4%) and glycine (1%) deposited more hydroxyproline (a component of collagen) in wounds that were healing when compared to animals fed control diets. Published studies have examined the effects of dietary argini.ne on cells of the immune system, such as T-lymphocytes and natural killer cells. Supplemental arginine may enhance immune function through increases in thymic weight and enhanced thymoc;yte and peripheral blood lymphocyte response to mitogens.
Similarly, published reports have indicated that surgical patients whose diets were supplemented with arginine (25g/day) exhibited increased T-lymphocyte activation compared with a group fed glycine. Another published study found that dietary L-arginine was important for lymphokine-activated killer cell activity. Other published studies have reported that diets providing 6% of total calories as arginine HCL were associated with an increased mortality in animal models of sepsis. The product of the present invention has 1-3% of the total calories provided by L-arginine.
The amino acid profile of the nutritional product of the present invention is presented in Table 3, and meets the standard for high biological protein set by the U.S. RDA
Committee.
AMINO ACID g/100g protein INDISPENSABLE TARGET PREFERRED
RANGE
Histidine 2.1 1:7 2.4 -Isoleucine 4.2 4:1 5.1 -Leucine 9.0 7:9 12.5 -Lysine 7.1 5:5 9.4 -Methionine 2.3 2.1 2.9 -Phenylalanine 4.1 3.5 4.9 -Threonine 4.0 3.9 5.3 -Tryptophan 1.2 1.1 2.0 -Valine 5.0 4.8 6.5 -DISPENSABLE
Alanine 3.3 2.9 4.4 -Arginine (Includes 12.1 9.0 14.0 -inherent arginine) Aspartic Acid 7.5 6.5 10.00 -Cystine 1.1 0.7 2.2 -Glutamic Acid 18.3 17.5 - 20.5 Glycine 1.5 1.5 1.9 -Proline 8.0 6.5 9.0 -Serine 4.9 4.8 5.1 -Tyrosine 4.2 3.7 5.1 -14a Carbohydrate is an important energy source for the injured individual as it is readily absorbed and utilized. It is the preferred fuel for the brain and red blood cells. The hyperglycemia of trauma is attributed to alterations in thE= hormonal milieu. This causes an increased rate, of gluconeogenesis in the presence of elevated glulcocorti.coid, catecholamine, insulin and a hyperglycemic state. The carbohydrate in the product of the present invention is preferably provided primarily by hydrolyzed corn starch. A commercially available hydrolyzed corn starch commodity is Maltrin 100 (Trade-mark) which is distributed by Grain Processing Corporation of Muscatine, Iowa, U.S.A.
Although the formulation presented in Table .L does not contain dietary fiber, it is considered to be within the scope of the ~>resent invention to employ dietary fiber in the nutritional product disclosed herein.
Numerous types of dietary fibers are currently available.
Basically, dietary fiber passes through the small intestine undigested by enzymes and is a kind of natural and necessary laxative. As used herein and in the claims, dietary fiber is understood to be all of the components of food that are nct. broken down by enzymes in the human digestive tract to produce small molecular compounds which are then absorbed into the bloodstream. A
nutritional product according to the invention has been made containing gum arabic or a source of dietary fiber.
Another possible fiber sources that may be employed in the product is thc~ blend of dietary fibers which is taught in commonly assigned U.S. Patent 5,085,883 issued February 4, 1992.
Lipids provide energy and essential fatty acids and enhance absorption of the fat soluble vitamins. The type of lipid consumed affects many physiological parameters such as plasma lipid profile, membrane lipid composition and synthesis of mediators of the immune response such as prostaglandins and i~:hromboxanes. Fat may be anappropriate fuel source for t:he hyperglycemic patient if peripheral tissues are insulin insensitive. The lipid system in the product of the pr~=sent invention preferably comprises canola oil, medium chain triglycerides (fractionated coconut oil) and corn oil. Canola oil provides alpha linolenic acid, l.inoleic acid and oleic acid. It is relatively low in saturated fat. The omega three-fatty acid provided by canola oil may have beneficial effects on the immune system, mediated through changes in the synthesis of prostaglandin. Corn oil is a source of Linoleic acid which is an essential fatty acid. Medium 15a chain triglyceride~; are a readily absorbed source of energy and are useful in meeting the caloric. need of stressed patients.
In a nutritional product according to the embodiment set forth in Table 1 the lipid system comprises by weight: (a) about 35-550, preferably about 35-45%, and most preferably about 38-42% canola oil; (b) about 30-50%, preferably about 35-45%, and most preferably about 38-42% medium chairs triglycerides (fractionated coconut oil: and (c) about 5--35-1, preferably about 10-30%, most WO 93/16595 ~ PCT/US93/0~'~10 preferably about 15-25% corn oil. It is believed, however, that a satisfactory nutritional product according to the present invention may be made having a lipid system comprising about 40%
medium chain triglycerides and about 60% canola oil. The lipid system provides a ratio of linoleic to alpha linolenic acid in the range of about 3.5:1 to about 5.5:1. The nutritional product of the present invention has about 4-5% of the total calories provided by the essential fatty acid linoleic acid.
It has been recommended in the prior art that critically ill patients be provided with this level of linoleic acid.
Preferably the fatty acid profile provided to the nutritional product is that set forth in Table 4.
WO 93/16595 PCf/US93/01100 ,~ : ~ ,-, n x7 .,~
fr; ~~ r 1,, _ FATTY ACID % Total Fatty Acids TARGET PREFERRED RANGE
Linoleic (18:2e6) 21 19 - 24 a-Linolenic (18:33) 4.5 3.5 - 12 NONEHBENTIAL
Caprylic (8:0) 23 18 - 26 Capric (10:0) 10.3 10.2 - 15.5 Lauric (12:0) 0.1 trace - 0.4 Myristic (14:0) 0.3 trace - 0.7 Palmitic (16:0) 5.0 4.0 - 7.2 Stearic (18:0) 1.7 trace - 1.9 Oleic (18:1~r9) 31 20 - 45 Arachidic (20:0) 0.4 trace - 0.6 Eiosenoic (20:19) 0.4 trace - 0.6 Others 2.3 trace -10 There is evidence that vitamin A may reverse some of the immunosuppression which occurs following thermal injury or radiation injury; therefore, additional vitamin A for trauma patients may be beneficial. In particular, the cellular immune system may be responsive to vitamin A as measured by enhanced mixed lymphocyte reactions in burned animals given supplemental vitamin A palmitate. One published study examined the effects of vitamin A on impaired wound healing which accompanies radiation. Supplemental vitamin A administered prior to or after radiation or injury prevented the impaired wound healing, gastric ulceration and thymic involution which is typically observed. Beta carotene does not have the toxicity problems of vitamin A and may be the preferred form to add supplemental retinol equivalents to the diet. Deta carotene itself may enhance immune system Function and functions as an antioxidant.
The nutritional product of the present invention contains both vitamin A and beta carotene.
WO 93/16595 PCT/US93/O11(10 Vitamin E acts as an antioxidant and plays a role in the immune system, and is present in the nutritional product at a level of at least 45 IU per 1,500 kcals.
Taurine (p-aminoethanesulfonic acid) is involved in a wide variety of metabolic processes, including those of the central nervous system. It is involved in the conjugation of bile acids, helps regulate the aggregation of platelets, and aids in the function of neutrophils. Synthesized via cysteine, taurine is classified as a sulfur-containing amino acid. It is considered nonessential for humans under normal physiologic circumstances, although a decline in serum taurine concentrations suggests that taurine supplementation is needed in the postinjury state. A published study of severely burned patients indicated that the metabolism of methionine and cysteine may be altered after injury.
Carnitine is required metabolically to transfer long-chain fatty acids into the mitochondria for energy production.
Carnitine is present in food, including meats and dairy products, and typical mixed diets provide 0.18 to 319 mg of carnitine/day. Published clinical trials have indicated that the excretion of carnitine increases after injury, and carnitine deficiency during antibiotic therapy has been reported. These results indicate that the supply of carnitine may be limited under certain circumstances and, therefore, should be supplied to trauma and major surgery patients.
Both taurine and carnitine are provided in a preferred embodiment of the present invention. The recommended intake of zinc is l5mg/day for a healthy adult, and inadequate zinc intake by "healthy" people is not uncommon. An inadequate intake of zinc is associated with skin lesions, poor wound healing and immunodeficiency characterized by thymic atrophy. Alterations in zinc metabolism occur after trauma. For example, sepsis is associated with a decreased serum zinc level and an accumulation of zinc within the liver. The product of the present invention provides at least 100% of the U.S. RUA of zinc. The product of the invention contains vitamin C and the B vitamins in amounts greater than the U.S.RDA for an amount of product sufficient to provide 1500 kcal to insure adequate for hypermetabolic patients.
WO 93/ 16595 '> y y ~ ~ '~ ~ PCT/US93/01100 ~s~~
The nutritional product of the present invention has a moderate osmolality of about 425 Mosm/ky water, even though the product contains partially hydrolyzed proteins and has a greater caloric density as compared to prior art formulations.
Formulations high in osmolarity may increase the risk of osmotic diarrhea. The nutritional product of the present invention has a viscosity of not greater than 55 cps, preferably about 25-45 cps, which is wnsistent with good tube feeding characteristics.
The nutritionz: :roduct of the present invention is intended primarily to Y: ~ed to a patient via a feeding tube in a manner which is well own in the art. However, it is considered to be within the sc: of this invention to add a flavoring system to allow oral feed«.,~.
Claims (26)
1. A liquid nutritional product comprising: a protein system comprising by weight about 20-30% lactalbumin hydrolysate, about 60-70% partially hydrolyzed sodium caseinate, and about 8-14% L-arginine, supplemental L-arginine providing about 1-3% of the total calories in the nutritional product; and a lipid system having a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5: 1 to about 5.5:1, said nutritional product having a caloric density in the range of about 1.2 to 1.5 kcal/ml and a calorie to nitrogen ratio of about 112:1 to about 145:1.
2. A liquid nutritional product according to claim 1 wherein the nutritional product has a caloric density of about 1.3 kcal/ml.
3. A liquid nutritional product according to claim 1 wherein about 18-24% of the calories are provided by protein, about 20-30% of the calories are provided by lipids, and about 46-62% of the calories are provided by carbohydrates.
4. A liquid nutritional product according to claim 2 wherein about 18-24% of the calories are provided by protein, about 20-30% of the calories are provided by lipids, and about 46-62% of the calories are provided by carbohydrates.
5. A liquid nutritional product according to claim 1 wherein the lipid system comprises by weight about 35-55% canola oil, about 30-50% medium chain triglycerides and about 5-35%
corn oil.
corn oil.
6. A liquid nutritional product according to claim 2 wherein the lipid system comprises by weight about 35-55% canola oil, about 30-50% medium chain triglycerides and about 5-35%
corn oil.
corn oil.
7. A liquid nutritional product according to claim 3 wherein the lipid system comprises by weight about 35-55% canola oil, about 30-50% medium chain triglycerides and about 5-35%
corn oil.
corn oil.
8. A liquid nutritional product according to claim 4 wherein the lipid system comprises by weight about 35-55% canola oil, about 30-50% medium chain triglycerides and about 5-35%
corn oil.
corn oil.
9. A liquid nutritional product according to any one of claims 1-8 further comprising hydrolyzed corn starch as a carbohydrate source.
10. A liquid nutritional product comprising:
(a) a protein system which provides about 18-24% of the calories provided by the product, said protein system including (i) partially hydrolyzed protein and (ii) supplemental L-arginine in an amount sufficient to provide about 1-3% of the total calories provided by the product;
(b) a lipid system which provides about 20-30% of the calories provided by the product, said lipid system having a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1; and (c) carbohydrates which provide about 46-62% of the calories provided by the product, the product having a caloric density in the range of about 1.2 to 1.5 kcal/ml a calorie to nitrogen ratio of about 112:1 to about 145:1, and having the following amino acid profile:
AMINO ACID g/100g protein Histidine 1.7 - 2.4 Isoleucine 4.1 - 5.1 Leucine 7.9 - 12.5 Lysine 5.5 - 9.4 Methionine 2.1 - 2.9 Phenylalanine 3.5 - 4.9 Threonine 3.9 - 5.3 Tryptophan 1.1 - 2.0 Valine 4.8 - 6.5 Alanine 2.9 - 4.4 Arginine (Includes inherent arginine) 9.0 - 14.5 Aspartic Acid 6.5 - 10.00 Cystine 0.7 - 2.2 Glutamic Acid 17.5 - 20.5 Glycine 1.5 - 1.9 Proline 6.5 - 9.0 Serine 4.8 - 5.1 Tyrosine 3.7 - 5.1
(a) a protein system which provides about 18-24% of the calories provided by the product, said protein system including (i) partially hydrolyzed protein and (ii) supplemental L-arginine in an amount sufficient to provide about 1-3% of the total calories provided by the product;
(b) a lipid system which provides about 20-30% of the calories provided by the product, said lipid system having a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1; and (c) carbohydrates which provide about 46-62% of the calories provided by the product, the product having a caloric density in the range of about 1.2 to 1.5 kcal/ml a calorie to nitrogen ratio of about 112:1 to about 145:1, and having the following amino acid profile:
AMINO ACID g/100g protein Histidine 1.7 - 2.4 Isoleucine 4.1 - 5.1 Leucine 7.9 - 12.5 Lysine 5.5 - 9.4 Methionine 2.1 - 2.9 Phenylalanine 3.5 - 4.9 Threonine 3.9 - 5.3 Tryptophan 1.1 - 2.0 Valine 4.8 - 6.5 Alanine 2.9 - 4.4 Arginine (Includes inherent arginine) 9.0 - 14.5 Aspartic Acid 6.5 - 10.00 Cystine 0.7 - 2.2 Glutamic Acid 17.5 - 20.5 Glycine 1.5 - 1.9 Proline 6.5 - 9.0 Serine 4.8 - 5.1 Tyrosine 3.7 - 5.1
11. A liquid nutritional product according to claim 10 wherein said product has the following fatty acid profile:
FATTY ACID % Total Fatty Acids Linoleic (18:2.omega.6) 19- 24 .alpha.-Linolenic (18:3.omega.3) 3.5- 12 Caprylic (8:0) 18 - 26 Capric (10:0) 10.2- 15.5 Lauric (12:0) trace - 0.4 Myristic (14:0) trace - 0.7 Palmitic (16:0) 4.0 - 7.2 Stearic (18:0) trace - 1.9 Oleic (18:1.omega.9) 20 - 55 Arachidic (20:0) trace- 0.6 Eiosenaic (20:1.omega.9) trace - 0.6 Others trace - 10
FATTY ACID % Total Fatty Acids Linoleic (18:2.omega.6) 19- 24 .alpha.-Linolenic (18:3.omega.3) 3.5- 12 Caprylic (8:0) 18 - 26 Capric (10:0) 10.2- 15.5 Lauric (12:0) trace - 0.4 Myristic (14:0) trace - 0.7 Palmitic (16:0) 4.0 - 7.2 Stearic (18:0) trace - 1.9 Oleic (18:1.omega.9) 20 - 55 Arachidic (20:0) trace- 0.6 Eiosenaic (20:1.omega.9) trace - 0.6 Others trace - 10
12. A liquid nutritional product according to claim 10 wherein the product has a caloric density of about 1.3 kcal/ml.
13. A liquid nutritional product according to claim 11 wherein the product has a caloric density of about 1.3 kcal/ml.
14. A liquid nutritional product according to claims 10 wherein the product has a viscosity of not greater than 55 cps.
15. A liquid nutritional product according to claim 11 wherein the product has a viscosity of not greater than 55 cps.
16. A liquid nutritional product according to claim 12 wherein the product has a viscosity of not greater than 55 cps.
17. A liquid nutritional product according to claim 13 wherein the product has a viscosity of not greater than 55 cps.
18. A liquid nutritional product according to any one of claims 10-17 further comprising a source of dietary fiber.
19. A liquid nutritional product comprising (a) a protein system comprising by weight about 20-30% lactalbumin hydrolysate, about 62-68% partially hydrolyzed sodium caseinate, and about 8-12% L-arginine, supplemental L-argimine providing about 1-3% of the total calories in the nutritional product;
(b) a lipid system comprising by weight about 35-45%
canola oil, about 35-45% medium chain triglycerides, and about 10-30% corn oil, the lipid system providing a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1: and (c) a carbohydrate system comprising hydrolyzed corn starch, the nutritional product having (i) a caloric density of about 1.3 kcal/ml, (ii) a caloric distribution such that about 18-24% of the calories are provided by proteins, about 20-30% of the calories are provided by lipids and about 46-62% of the calories are provided by carbohydrates, (iii) the nutritional product has a viscosity of not greater than 55 cps, and (iv) a calorie to nitrogen ratio of about 112:1 to about 145:1.
(b) a lipid system comprising by weight about 35-45%
canola oil, about 35-45% medium chain triglycerides, and about 10-30% corn oil, the lipid system providing a ratio of linoleic acid to alpha linoleic acid in the range of about 3.5:1 to about 5.5:1: and (c) a carbohydrate system comprising hydrolyzed corn starch, the nutritional product having (i) a caloric density of about 1.3 kcal/ml, (ii) a caloric distribution such that about 18-24% of the calories are provided by proteins, about 20-30% of the calories are provided by lipids and about 46-62% of the calories are provided by carbohydrates, (iii) the nutritional product has a viscosity of not greater than 55 cps, and (iv) a calorie to nitrogen ratio of about 112:1 to about 145:1.
20. A liquid nutritional product according to claim 19 further comprising carrageenan.
21. A liquid nutritional product according to claim 19 wherein a quantity of said product sufficient to provide 1,500 kcal will provide at least 100% of the U. S. RDA of Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin C, Folic Acid, Thiamin, Riboflavin, Vitamin B-6, Vitamin B-12, Niacin, Biotin, Pantothenic Acid, Calcium, Phosphorus, Magnesium, Iodine, Copper, Zinc and Iron.
22. A liquid nutritional product according to claim 20 wherein a quantity of said product sufficient to provide 1,500 kcal will provide at least 100% of the U. S. RDA of Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin C, Folic Acid, Thiamin, Riboflavin, Vitamin B-6, Vitamin B-12, Niacin, Biotin, Pantothenic Acid, Calcium, Phosphorus, Magnesium, Iodine, Copper, Zinc and Iron.
23. A liquid nutritional product according to claim 19 further comprising beta carotene.
24. A liquid nutritional product according to claim 20 further comprising beta carotene.
25. A liquid nutritional product according to claim 21 further comprising beta carotene.
26. A liquid nutritional product according to claim 22 further comprising beta carotene.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/840,972 US5221668A (en) | 1992-02-26 | 1992-02-26 | Nutritional product for trauma and surgery patients |
US840,972 | 1992-02-26 | ||
PCT/US1993/001100 WO1993016595A1 (en) | 1992-02-26 | 1993-02-08 | Nutritional product for trauma and surgery patients |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2128078A1 CA2128078A1 (en) | 1993-09-02 |
CA2128078C true CA2128078C (en) | 2002-03-19 |
Family
ID=25283701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002128078A Expired - Lifetime CA2128078C (en) | 1992-02-26 | 1993-02-08 | Nutritional product for trauma and surgery patients |
Country Status (12)
Country | Link |
---|---|
US (1) | US5221668A (en) |
EP (1) | EP0630181B1 (en) |
JP (1) | JP2644086B2 (en) |
AU (1) | AU3614393A (en) |
CA (1) | CA2128078C (en) |
DE (1) | DE69325091T2 (en) |
DK (1) | DK0630181T3 (en) |
GR (1) | GR3030642T3 (en) |
HK (1) | HK1011597A1 (en) |
MX (1) | MX9300999A (en) |
NZ (1) | NZ249392A (en) |
WO (1) | WO1993016595A1 (en) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005780A1 (en) * | 1990-10-01 | 1992-04-16 | Brigham And Women's Hospital | Beta-carotene and vitamin e therapy for inhibition of major vascular events |
US5571783A (en) * | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
US5714161A (en) * | 1993-04-22 | 1998-02-03 | Colgate Palmolive Company | Syringeable enteral diet for animals in a hypermetabolic state caused by the stress of medical and surgical illness |
US5424299A (en) * | 1993-04-23 | 1995-06-13 | Monte; Woodrow C. | Composition and method for rejuvenating enteral feeding tubes |
US5514655A (en) * | 1993-05-28 | 1996-05-07 | Abbott Laboratories | Enteral nutritional with protein system containing soy protein hydrolysate and intact protein |
US5403826A (en) * | 1993-05-28 | 1995-04-04 | Abbott Laboratories | Nutritional product for persons infected with human immunodeficiency virus |
US5514656A (en) * | 1993-05-28 | 1996-05-07 | Abbott Laboratories | Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy |
US5547927A (en) * | 1993-05-28 | 1996-08-20 | Abbott Laboratories | Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy |
US5480872A (en) * | 1993-05-28 | 1996-01-02 | Abbott Laboratories | Method of providing enternal nutritional support to persons infected with human immunodeficiency virus |
US5700782A (en) * | 1993-05-28 | 1997-12-23 | Abbott Laboratories | Enteral nutritional product |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
GB9318611D0 (en) * | 1993-09-08 | 1993-10-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
US5438042B1 (en) * | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
US5723446A (en) * | 1993-12-23 | 1998-03-03 | Nestec Ltd. | Enteral formulation designed for optimized nutrient absorption and wound healing |
US5714472A (en) * | 1993-12-23 | 1998-02-03 | Nestec Ltd. | Enternal formulation designed for optimized nutrient absorption and wound healing |
US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
US5656588A (en) * | 1994-07-19 | 1997-08-12 | Wake Forest University | Wound healing formula |
US5550113A (en) * | 1994-07-20 | 1996-08-27 | Mann; Morris A. | Blood sugar regulating composition and methods relating thereto |
US5578576A (en) * | 1994-09-02 | 1996-11-26 | Dalhousie University | Method and composition for treating intestinal wounds or ulcers |
US6190704B1 (en) * | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
US5589468A (en) * | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
US5817351A (en) * | 1995-04-07 | 1998-10-06 | Abbott Laboratories | Calcium fortified low pH beverage |
US5698222A (en) * | 1995-04-07 | 1997-12-16 | Abbott Laboratories | Calcium supplement |
US5597595A (en) * | 1995-04-07 | 1997-01-28 | Abbott Laboratories | Low pH beverage fortified with calcium and vitamin D |
US6039989A (en) * | 1995-06-06 | 2000-03-21 | Campbell Soup Company | Prepackaged therapeutic meal for treatment of diet-responsive conditions |
WO1996039052A2 (en) * | 1995-06-06 | 1996-12-12 | Campbell Soup Company | Compliance support package for increasing health management system compliance |
EP0833570A1 (en) * | 1995-06-06 | 1998-04-08 | Campbell Soup Company | Therapeutic system for dietary health management |
CA2222278C (en) * | 1995-06-06 | 2008-05-13 | Campbell Soup Company | Mineral supplements for dietetic food |
US5639471A (en) * | 1995-06-06 | 1997-06-17 | Campbell Soup Company | Method for determining diet program effectiveness |
DE19528461A1 (en) * | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Preparation for nutrition |
US5635199A (en) * | 1995-10-27 | 1997-06-03 | Nestec Ltd. | Support of pediatric patients |
US5733884A (en) | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
ES2132021B1 (en) * | 1997-05-28 | 2000-02-16 | Riera Simon Schwartz | AMINO ACID FORMULAS FOR PERSONS OF THE OLDER AGE AND PROCEDURE FOR THE CALCULATION OF THE SAME. |
US6281244B1 (en) * | 1997-06-05 | 2001-08-28 | Novartis Nutrition Ag | Therapeutic use for glycine |
ES2265669T3 (en) * | 1997-09-16 | 2007-02-16 | Societe Des Produits Nestle S.A. | USE OF A SPECIFIC NUTRITIVE COMPOSITION FOR AN ORGAN. |
US6200950B1 (en) | 1998-02-18 | 2001-03-13 | Nestec S.A. | Calorically dense nutritional composition |
US20050196470A9 (en) * | 1998-04-03 | 2005-09-08 | Wuh Hank C | Method and composition for enhancing sexual desire |
AU3221599A (en) * | 1998-04-03 | 1999-10-25 | Daily Wellness Company, The | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
US6194379B1 (en) | 1998-05-01 | 2001-02-27 | Abbott Laboratories | Elemental enteral formula |
EP0960572A1 (en) * | 1998-05-12 | 1999-12-01 | N.V. Nutricia | Nutritional composition for the treatment of pressure ulcers |
US6288116B1 (en) | 1998-05-13 | 2001-09-11 | Novartis Nutrition Ag | Method of administration of a nutritional product to a person having renal failure |
US7141266B2 (en) * | 1998-05-21 | 2006-11-28 | Beech-Nut Nutrition Corporation | Baby-food compositions enhancing visual acuity and methods therefor |
US7413759B2 (en) * | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
US6579551B1 (en) | 1998-05-21 | 2003-06-17 | Beech-Nut Nutrition Corporation | Baby-food compositions containing egg yolk and methods therefor |
US6149964A (en) * | 1998-05-21 | 2000-11-21 | Beech-Nut Nutrition Corporation | Egg yolk-containing baby food compositions and methods therefor |
US6245379B1 (en) | 1998-09-30 | 2001-06-12 | The Iams Company | Method of administering a milk substitute to critical care animals |
EP1023843B1 (en) * | 1999-01-29 | 2005-06-22 | Sportmedizin Team Vertriebs GmbH | Composition for improving performance during sportive activities, its production and use as dietetic food product |
GB9923048D0 (en) * | 1999-09-29 | 1999-12-01 | Nestle Sa | Composition comprising casein protein and whey protein |
RU2275041C2 (en) * | 1999-04-29 | 2006-04-27 | Сосьете Де Продюи Нестле С.А. | Composition of milk mixture, method for producing the same and milk mixture including composition (versions) |
IL141250A0 (en) * | 1999-06-05 | 2002-03-10 | Univ Leland Stanford Junior | Method and composition for inhibiting cardiovascular cell proliferation |
US6838431B2 (en) * | 1999-07-27 | 2005-01-04 | Pacific Health Laboratories, Inc. | Nutritional intervention composition containing a source of proteinase inhibitor extending post meal satiety |
BR0006959A (en) * | 1999-07-27 | 2001-06-26 | Kemin Ind Inc | Nutritional composition in a dry powder form |
EP1090636A1 (en) * | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | High lipid diet |
US6214373B1 (en) * | 1999-10-07 | 2001-04-10 | Snowden-Sutton Associates, Inc. | Nutritional composition for treating inflammatory bowel diseases |
AU784123B2 (en) * | 1999-10-13 | 2006-02-09 | Marco A. Chacon | Therapeutic intervention to mimic the effect of caloric restriction |
SE523432C2 (en) * | 2000-01-12 | 2004-04-20 | Mjoelkkannan Foervaltning Ab C | Nutritional Drink |
US6989164B2 (en) * | 2000-12-22 | 2006-01-24 | The Daily Wellness Company | Method and composition for improving male fertility health |
US6497885B2 (en) * | 2000-12-22 | 2002-12-24 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
US7740893B2 (en) * | 2001-04-02 | 2010-06-22 | Mott's Llp | Sports drink composition for enhancing glucose uptake into the muscle and extending endurance during physical exercise |
US6989171B2 (en) * | 2001-04-02 | 2006-01-24 | Pacifichealth Laboratories, Inc. | Sports drink composition for enhancing glucose uptake into the muscle and extending endurance during physical exercise |
US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
KR20010070584A (en) * | 2001-05-25 | 2001-07-27 | 한승관 | The manufacture and utilization methods of a new functional material utilizing nitric oxide and linoleic acid |
US6605310B2 (en) | 2001-06-06 | 2003-08-12 | Nestec S.A. | Calorically dense liquid oral supplement |
US7345091B2 (en) * | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US7763649B2 (en) * | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
US20050059659A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
US20050026874A1 (en) * | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
US20050049248A1 (en) * | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
US7375133B2 (en) * | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US7320997B2 (en) * | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
MXPA05001202A (en) * | 2002-07-29 | 2005-11-23 | Hawaii Biotech Inc | Structural carotenoid analogs for the inhibition and amelioration of disease. |
US7521584B2 (en) * | 2002-07-29 | 2009-04-21 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of disease |
US20050059635A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
US20050009788A1 (en) * | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
US7723327B2 (en) * | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
US20050148517A1 (en) * | 2002-07-29 | 2005-07-07 | Lockwood Samuel F. | Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
US20050143475A1 (en) * | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
US20050004235A1 (en) * | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
US8100879B2 (en) | 2002-11-18 | 2012-01-24 | Nestec S.A. | Connector device for enteral administration set |
CN100415224C (en) * | 2003-03-18 | 2008-09-03 | 诺瓦提斯公司 | Compositions comprising fatty acids and amino acids |
EP1475434A1 (en) * | 2003-05-09 | 2004-11-10 | Oncoscience AG | Method for storing tumor cells |
US20050192210A1 (en) * | 2004-03-01 | 2005-09-01 | Rothbard Jonathan B. | Compositions and methods for treating diseases |
US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
EP1750723A1 (en) * | 2004-04-14 | 2007-02-14 | Hawaii Biotech, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20050271726A1 (en) * | 2004-06-02 | 2005-12-08 | Albert Crum | Immune enhancing compositions and methods of use thereof |
US20060286208A1 (en) * | 2005-06-01 | 2006-12-21 | Nagendra Rangavajla | Methods for producing protein partial hydrolysates and infant formulas containing the same |
US7618669B2 (en) * | 2005-06-01 | 2009-11-17 | Mead Johnson Nutrition Company | Low-lactose partially hydrolyzed infant formula |
US8883814B2 (en) | 2006-06-05 | 2014-11-11 | Keyview Labs, Inc. | Compositions and methods for enhancing brain function |
US10105405B2 (en) | 2006-06-05 | 2018-10-23 | Keyview Labs, Inc. | Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A and ginkgo biloba |
US20070281961A1 (en) * | 2006-06-05 | 2007-12-06 | Brite Age | Modified Compositions And Methods For Enhancing Brain Function |
US9308232B2 (en) | 2006-06-05 | 2016-04-12 | Keyview Labs, Inc. | Compositions and methods for enhancing brain function |
US10105406B2 (en) | 2006-06-05 | 2018-10-23 | Keyview Labs, Inc. | Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A, Ginkgo biloba, and vitamin B complex |
US8071610B2 (en) * | 2006-06-05 | 2011-12-06 | Josh Reynolds | Compositions and methods for enhancing brain function |
US20080050486A1 (en) * | 2006-08-23 | 2008-02-28 | Shengying Zhou | Method For Suppression of Fishy Aromas In Food Products By Proteins |
US20080145506A1 (en) * | 2006-12-18 | 2008-06-19 | Bodybio, Inc. | Food compositions and products containing balanced ratio of essential fatty acids |
WO2009126932A2 (en) * | 2008-04-10 | 2009-10-15 | Provide Nutrition | Fortified liquid protein compositions and methods of making same |
EP2398472A2 (en) * | 2009-01-14 | 2011-12-28 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Methods and preparations for protecting critically ill patients with a polyamine (e.g. spermine, spermidine) |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
SG11201504690YA (en) | 2012-12-18 | 2015-07-30 | Abbott Lab | Low viscosity, high caloric density oral nutritional composition and related methods |
MX2015012546A (en) * | 2013-03-12 | 2016-06-02 | Abbott Lab | Composition comprising a multifunctional viscosity modifying agent. |
US10568337B1 (en) * | 2014-04-30 | 2020-02-25 | Jayson Calton | Method and composition for providing liquid coconut oil |
EP3411016A1 (en) * | 2016-02-03 | 2018-12-12 | Fresenius Kabi Deutschland GmbH | High caloric, high protein nutritional formula |
ES2737950T3 (en) * | 2016-09-23 | 2020-01-17 | Fresenius Kabi Deutschland Gmbh | Liquid nutritional compositions rich in calories treated by UHT |
AU2017361804B2 (en) * | 2016-11-16 | 2021-09-09 | Fresenius Kabi Deutschland Gmbh | Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients |
US11147835B1 (en) | 2020-08-20 | 2021-10-19 | Frank Kelly Reilly, III | Nutritional supplement |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042688A (en) * | 1975-11-24 | 1977-08-16 | Control Drug, Inc. | Method of providing high-protein nutrition by the oral administration of a predigested protein composition |
US4438144A (en) * | 1980-07-31 | 1984-03-20 | Blackburn George L | Amino acid preparation and therapy for treatment of stress and injury |
FR2556593B1 (en) * | 1983-12-20 | 1987-01-02 | Synthelabo | NUTRITIONAL COMPOSITION CONTAINING ALPHA-CETOISOCAPROIC ACID, LEUCIN AND ESSENTIAL AND NON-ESSENTIAL AMINO ACIDS |
JPS61192245A (en) * | 1985-02-21 | 1986-08-26 | Snow Brand Milk Prod Co Ltd | Powdery milk containing arginin |
US4850704A (en) * | 1986-08-28 | 1989-07-25 | Ladish Co. | Two stage blender |
US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
US5053387A (en) * | 1987-02-20 | 1991-10-01 | Shriners Hospitals For Crippled Children | Omega-3 fatty acids in traumatic injury treatment |
WO1988008259A1 (en) * | 1987-05-01 | 1988-11-03 | Otsuka Pharmaceutical Co., Ltd. | Nutritive emulsion preparation |
EP0362724A3 (en) * | 1988-10-07 | 1991-10-09 | BASF Aktiengesellschaft | Thermoplastic moulding compositions |
ES2146199T3 (en) * | 1989-12-29 | 2000-08-01 | Braun Medical Inc | USE OF ARGININE AS AN IMMUNOSTIMULANT. |
US5085883A (en) * | 1991-06-27 | 1992-02-04 | Abbott Laboratories | Blend of dietary fiber for nutritional products |
-
1992
- 1992-02-26 US US07/840,972 patent/US5221668A/en not_active Expired - Lifetime
-
1993
- 1993-02-08 CA CA002128078A patent/CA2128078C/en not_active Expired - Lifetime
- 1993-02-08 AU AU36143/93A patent/AU3614393A/en not_active Abandoned
- 1993-02-08 DK DK93904966T patent/DK0630181T3/en active
- 1993-02-08 DE DE69325091T patent/DE69325091T2/en not_active Expired - Lifetime
- 1993-02-08 EP EP93904966A patent/EP0630181B1/en not_active Expired - Lifetime
- 1993-02-08 WO PCT/US1993/001100 patent/WO1993016595A1/en active IP Right Grant
- 1993-02-08 JP JP5514876A patent/JP2644086B2/en not_active Expired - Fee Related
- 1993-02-08 NZ NZ249392A patent/NZ249392A/en not_active IP Right Cessation
- 1993-02-24 MX MX9300999A patent/MX9300999A/en unknown
-
1998
- 1998-11-30 HK HK98112597A patent/HK1011597A1/en not_active IP Right Cessation
-
1999
- 1999-06-30 GR GR990401728T patent/GR3030642T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
GR3030642T3 (en) | 1999-10-29 |
MX9300999A (en) | 1993-09-01 |
NZ249392A (en) | 1996-01-26 |
DK0630181T3 (en) | 1999-11-15 |
EP0630181A4 (en) | 1995-07-26 |
AU3614393A (en) | 1993-09-13 |
EP0630181A1 (en) | 1994-12-28 |
JP2644086B2 (en) | 1997-08-25 |
HK1011597A1 (en) | 1999-07-16 |
CA2128078A1 (en) | 1993-09-02 |
WO1993016595A1 (en) | 1993-09-02 |
EP0630181B1 (en) | 1999-05-26 |
JPH07500348A (en) | 1995-01-12 |
US5221668A (en) | 1993-06-22 |
DE69325091T2 (en) | 1999-12-23 |
DE69325091D1 (en) | 1999-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2128078C (en) | Nutritional product for trauma and surgery patients | |
KR101075816B1 (en) | Total enteral nutritious composition | |
US5700782A (en) | Enteral nutritional product | |
EP0764405B1 (en) | Nutritional composition | |
US6440470B2 (en) | Elemental enteral nutritional product | |
CA2133783C (en) | Enteral nutritional composition | |
Souba et al. | Oral glutamine reduces bacterial translocation following abdominal radiation | |
FI58579B (en) | ANALYSIS OF HOUSE-AMYLOSSTAERKELSE VID FRAMSTAELLNING AV EN DIETFOEDOAEMNESKOMPOSITION | |
US5723446A (en) | Enteral formulation designed for optimized nutrient absorption and wound healing | |
US5719133A (en) | Adolescent dietary composition | |
US4753926A (en) | Infant foods | |
TWI429405B (en) | Pediatric amino acid solution for parenteral nutrition | |
KR960003888B1 (en) | Liquid nutritional formula for glucose intolerance | |
AU2003230958A1 (en) | Composition for enhancing nutritional content of food | |
EP0656782A1 (en) | Nutritional product for persons having a neurological injury | |
JP2002504501A (en) | Products and methods for reducing stress-induced immunosuppression | |
US5849335A (en) | Composition and method for providing glutamine | |
AU2004241884A1 (en) | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | |
JPH07147932A (en) | Liquid high-energy food | |
CA2319158A1 (en) | Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby | |
Lagua | T. Abbreviation for temperature. T3• Abbreviation for triiodothyronine, a thyroid hormone. See Thyroid gland. T 4'Abbreviation for tetraiodothyronine | |
Blažek et al. | The Effect of α-Tocopherol Acetate on Plasma Esterified Cholesterol in Patients with Chronic Liver Disease/Einfluß des α-Tokopherolazetats auf Plasmacholesterolester bei Kranken mit chronischen Leberstörungen/L'action de l'acétate d'α-tocophérol sur la fraction estérifiée du cholésterol plasmatique chez les malades souffrant d'affections hépatiques chroniques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20130208 |